

Base Induced Chiral Substituted Furans and Imidazoles from Carbohydrate-Derived 2-Haloenones

Kanchan Mal and Indrajit Das*

Organic and Medicinal Chemistry Division, CSIR-Indian Institute of Chemical Biology, 4, Raja S. C. Mullick Road, Jadavpur, Kolkata 700 032, India





ABSTRACT: Chiral substituted furans and imidazoles are key intermediates to access biologically important molecules. We describe herein a catalyst/ligand free cascade Michael-type addition/intramolecular cyclization/carbohydrate-ring opening of 2-haloenones with 1,3-dicarbonyl compounds or amidines utilizing K₂CO₃/DMSO at ambient temperature that provides a straightforward approach to a variety of optically active (poly)hydroxy furans and imidazoles containing multiple stereocenters with good yield and excellent regioselectivity. The furan intermediates provide efficient access to synthetically valuable substituted α -benzyloxyvinyl ketones. The NMR spectrum of the substituted 2-methylfurans shows an unusual long-range (${}^{5}J_{H-H}$) ${}^{1}H-{}^{1}H$ COSY cross-peak between C₂-CH₃ and C₄-H signals.

INTRODUCTION

Substituted furans, constituting the core structural unit in numerous biologically active natural products, pharmaceuticals, and significant synthetic intermediates, are highly sought-after in heterocyclic chemistry.^{1a-f} In particular, trisubstituted furans bearing an ester or keto-group at C-3 are extremely useful intermediates and promising building blocks in synthetic processes (Figure 1).^{1g,h} Chiral substituted furanyl α -ketones too form prominent structural motifs present in value-added compounds.^{2a} More significantly, the ketones after reduction to furanyl α -carbinols can be easily transformed under Achmatowicz reaction conditions to versatile synthetic intermediates,^{2b} which can be further transformed to modified higher-carbon sugars and aza sugars.^{2a} Like substituted furans, substituted imidazoles/ optically active (poly)hydroxy-substituted imidazoles are also commonly found in many biologically relevant natural products (Figure 1), with applications in target-oriented synthesis, N-heterocyclic carbene precursors, and ionic liquids.³

The chiral furanyl α -ketones/ α -carbinols are prepared either by using asymmetric Friedel–Crafts reaction or chiral pool precursors, or by enzymatic as well as kinetic resolutions of racemic mixtures.⁴ There are also sporadic reports on efficient synthetic strategies for optically active (poly)hydroxy-substituted imidazoles,⁵ In spite of these, the development of efficient and regioselective routes to these essential scaffolds utilizing operationally simple processes under mild reaction conditions is still in great demand.

Carbohydrates have been recognized as one of the most potential sources of chirality in target oriented synthesis of complex molecules.⁶ In particular, 2-iodoenones/enones 1 derived from carbohydrates are important synthetic intermediates for diverse reactions such as Diels-Alder reaction, Michael-type addition and Heck-type reaction/1,4-addition for C-glycosylation [A, Scheme 1a].⁷ Recently, we have described the synthesis of substituted chiral 3-formylfurans from these 2-iodoenones 1 [B, Scheme 1b].⁸ This finding prompted us to investigate whether the combination of such haloenones 1 with bidentate nucleophiles such as amidines or with active methylene compounds could constitute an unprecendented cascade annulation process to afford the optically active substituted imidazoles 2 and furans 3. Herein, we report the successful execution of this hypothesis by utilizing amidines and active methylene compounds through Michael-type addition followed by substitution and rearrangement.

RESULTS AND DISCUSSION

To optimize the reaction conditions for chiral imidazole derivatives, we initiated screening studies by utilizing 1a as the substrate and benzamidine hydrochloride as the 1,3-dinucleophilic species in the presence of different bases and solvents. Pleasantly, use of K_2CO_3 (3 equiv) as a base in DMSO led to the formation of a product which from preliminary spectroscopic analysis

Received: October 30, 2015 Published: January 8, 2016





Figure 1. Pharmacologically active and naturally occurring compounds containing chiral substituted imidazoles and furan-3-carboxylic acid esters.

Scheme 1. Previous Work from 1 and Our Hypothesis for Accessing Chiral Substituted Imidazoles and Furans

(a) General reported reactions with carbohydrate-derived substituted 2-iodoenones/enones (ref 7)



appeared to be 2a' (Table 1). Due to the unusual signal broadening in ¹³C NMR and difficulty in purification by column chromatography, this was acetylated with Ac₂O to isolate 2a, which could be easily spectrally analyzed, in 84% overall yield (Table 1, entry 1). As demonstrated in Table 1, different bases such as KO^tBu, Na₂CO₃, Cs₂CO₃, Ag₂CO₃, Li₂CO₃, KOH, DBU, or Et₃N could all initiate this transformation, but the product 2a was formed either in lower yields or it was necessary to conduct the reaction for a longer period (entries 2-9, Table 1). Furthermore, employing K₂CO₃ in lower ratios (2.0 equiv)/(1.0 equiv) only reduced the yields (entries 10–11, Table 1), while the reaction did not proceed at all in absence of a base (entry 16). The use of other solvents (DMF, THF, 1,4-dioxane, and CH₃CN; entries 12–15, Table 1) also failed to deliver the required products in good yields. More importantly, despite the use of basic reaction conditions (K_2CO_3) , no racemization was observed in the stereogenic center next to the carbonyl group. Thus, we concluded that the combination of K₂CO₃ (3.0 equiv) and DMSO at room temperature (entry 1, Table 1) constitutes the optimum reaction conditions.


We next examined the substrate scope and generality of the approach using various 2-haloenones 1 (Figure 2)^{7c,8,9} and aromatic/aliphatic amidines (Table 2). It is noteworthy that

the electronic nature and location of the substituents on the aromatic/aliphatic ring of amidines or substitution/protection at carbohydrate components 1 did not influence the outcome of the reactions significantly (Table 2). In general, 2-iodoenones 1a-e reacted with aromatic amidines containing an electronneutral, electron-donating, or electron-deficient substituents on the aromatic ring or with aliphatic amidines such as tertbutylcarboxamidine hydrochloride or cyclopropylcarboxamidine hydrochloride to give chiral 2-substituted-imidazoles with (poly)hydroxylated side chains in moderate to excellent yields (2a-v, Table 2). 2-Bromoenone (1g) also underwent similar conversion (to 2a, 2f, and 2n, Table 2) under standard conditions, but the yields were 58-60%. The drop in yield with bromoenone compared to iodoenones may be due to the poor leaving character of bromide. To demonstrate the versatility of our developed approach, the same sequence of reactions was carried out with 1a or 1b, and the product obtained was iodinated (rather than acetylation) to produce optically active 5-iodoimidazoles 2w and 2x (Table 2).

We next turned our attention to explore the substrate scope and generality of the reaction using various 2-haloenones 1 and 1,3-dicarbonyl compounds under similar reaction conditions. As shown in Table 3, the reaction is tolerant of variation in

Article

Table 1. Optimization of Reaction Conditions⁴



^{*a*}All reactions were carried out with 1a (0.03 g, 0.067 mmol, 1.0 equiv), benzamidine hydrochloride (0.01 g, 0.067 mmol, 1.0 equiv), base (equiv/mmol), and solvent (1.0 mL/equiv) in open air at rt. The product obtained was acetylated with Ac_2O , py, DMAP at 0 °C for 1 h. Yields are of isolated products in two-step. ^{*b*}Not detected; starting materials isolated.




Figure 2. Substituted 2-haloenones 1a-g derived from glycals used in this study.

substituents in the substituted haloenones and active methylenes, which were smoothly converted into the corresponding optically active substituted furanyl- α -ketones in moderate to good yields and with an excellent level of regioselectivity (3a-z, Table 3). The drop in yield with a TBDPS group instead of benzyl group might be due to the hydrolysis of the primary silyl protection under strongly basic conditions (3s, Table 3). The reaction did not work well with β -diketones (3t-u, Table 3) compared to the other active methylene compounds, although the exact reason is not very clear at this moment.


The structures of selected optically active substituted imidazoles (2a, 2g, 2i, and 2q) and furans (3a, 3c, 3f, 3k, 3r, and 3y) were established by extensive 1D and 2D NMR analyses, while those of other products 2 and 3 were assigned by comparison of the 1D NMR chemical shift values for the characteristic resonances (see Figure 3 and the Supporting Information for details). In addition, the single-crystal X-ray analysis of the α -benzyloxyvinyl ketone 5a was carried out to confirm the proposed structure (see Scheme 4, vide infra). It must be mentioned here that, though we indicate the formation of only one imidazole tautomer (Table 2), a perusal of the literature reveals that extremely fast proton transfers,

depending upon solvent polarity and temperature, occur in solution between two tautomers of imidazole derivatives and these are indistinguishable by NMR technique.^{5c,10} Therefore, the chiral imidazoles **2** might also exist in equilibrium between two tautomers and which are too fast in the NMR time scale.

Interestingly, during the analyses of the ${}^{1}\text{H}{-}{}^{1}\text{H}$ COSY NMR experiments (2D) for substituted furans, we are surprised to observe the long-range (${}^{5}J_{\text{H}-\text{H}}$) cross-peak between C₂-CH₃ and C₄-H signal for all the tested substituted 2-methyl furans (**3a**, **3f**, **3k**, and **5a**), which is quite unexpected and extremely rare in the literature (see the Supporting Information).¹¹ The zigzag pathway (W-type coupling) between the concerned protons may account for this unusual correlation.

In order to gain insights into the mechanistic pathway, several control experiments were carried out (Scheme 2). When the reaction of 1a and benzamidine hydrochloride was conducted with TEMPO (1.0 equiv) under optimized conditions, exclusive formation of 2a in 71% yield occurred, ruling out the possibility of any radical reaction pathway (Scheme 2). To determine whether atmospheric oxygen (open air) has any effect in this cascade, the reaction was conducted under Ar atmosphere. This

Table 2. Substrate Scope for Chiral Substituted Imidazoles^a




^aIsolated yields of 2 in two-step utilizing 2-iodoenones as substrates. ^bIsolated yields of 2a, 2f, and 2n from 2-bromoenone 1g.

afforded **2a** in 84% yield, thus suggesting no role for atmospheric oxygen in the proposed mechanism. Moreover, when **1a** was subjected to the standard conditions with benzylamine, morpholine, or phenyl hydrazine hydrochloride, only degradation of the starting materials took place, may be due to the lack of 1,3-dinucleophilic species. This experiment also supports the formation of intermediate **IV** as a carbohydrate-imidazolium-based intermediate as described in Scheme **3**. Furthermore, to

confirm whether the substrates with a conjugated α,β -unsaturated α -iodocarbonyl are necessary, we performed two parallel experiments with **4a** and **4b**¹² under optimized reaction conditions (Scheme 2). However, no expected product was ever observed even upon heating the reaction mixture for several hours, thus suggesting that the formation of optically active imidazoles **2** may proceed through 1,4-addition (Michael-type addition) followed by intramolecular nucleophilic ring closure.

Table 3. Substrate Scope for Chiral Substituted Furans^a



^{*a*}Isolated yields of **3** utilizing 2-iodoenones as substrates. The ratio of furan **3** and its regioisomer **4** was measured based on ¹H NMR analysis of the crude reaction mixture. The minor or trace products **4** proved inseparable by chromatography. ^{*b*}Inseparable mixtures. ^{*c*}Isolated yield of **3v** from 2-bromoenone **1g**.

Based on the experimental results given in Tables 2 and 3, the control experiments described in Scheme 2, and literature reports for Michael-type additions to carbohydrate-derived

enones,^{7b-d,f} a plausible mechanism for this novel cascade reaction is outlined in Scheme 3. We presume that initial base-induced Michael-type addition reaction of amidines or





Figure 3. Key COSY and HMBC correlations observed with 2a, 3a, and 3k (stereochemistry omitted for clarity).

Scheme 2. Control Experiments





1,3-dicarbonyl compounds to the haloenone 1 could lead to haloenolate I, which undergoes immediate proton transfer to generate intermediate II through enol-keto tautomerism. Intermediate II could form another enolate III and subsequent intramolecular nucleophilic attack by nitrogen (for imidazoles) or oxygen (for furans) to eliminate the halogen produces the corresponding intermediate IV. This would then collapse by base-catalyzed sugar-ring opening via alkoxide elimination, leading to the formation of **3** via protonation of intermediate **V**. For imidazole derivatives, **V** could undergo a prototropic tautomerism to produce **2a**'. Unfortunately, attempts to isolate any of the proposed intermediates were unsuccessful. On the other hand, the formation of the minor/trace product **4** could be explained by base-mediated formation of an activated 1,2-cyclopropanated sugar **VI**, which undergoes intramolecular rearrangement to produce intermediate **VII**, as described in the literature.¹³ This intermediate could then follow the pathway as described earlier for **3** in the proposed reaction mechanism (Scheme 3).

The efficacy of these developed procedures was demonstrated by accessing 2a, 3a, and 3k on a large scale without any significant diminution in the yield (Table 4). Furthermore, to highlight the potentiality of these intermediates, the conversion of substituted furans 3z and 3b to synthetically valuable α -benzyloxyvinyl ketones 5a-b was achieved in two steps (Scheme 4). The structure of 5a was unambiguously established by single-crystal X-ray diffraction analysis (Scheme 4).¹⁴

CONCLUSION

In conclusion, we have developed a general and catalyst/ligand free cascade for the construction of chiral substituted imidazoles and furans under basic conditions at ambient temperature, utilizing readily available and inexpensive carbohydrates and amidines/1,3-dicarbonyls as starting materials. This cascade







937

Article

Table 4. Scale-Up Batches for Chiral Derivatives



Scheme 4. Synthetic Transformations to Furan-Derived α -Benzyloxyvinyl Ketones



annulations process provides a straightforward access to these valuable scaffolds with good yields and excellent regioselectivity. The furan intermediates provide efficient access to synthetically valuable substituted α -benzyloxyvinyl ketones. The substituted 2-methylfurans show an intense long-range (${}^{5}J_{H-H}$) cross-peak between C_2 -CH₃ and C_4 -H in ${}^{1}H-{}^{1}H$ COSY NMR experiments, which is rare in the literature. Further applications of these carbohydrate-derived 2-haloenones as potentially important synthetic precursors are being explored in our laboratory.

EXPERIMENTAL SECTION

General Information. Melting points were determined in openend-capillary tubes and are uncorrected. TLC was performed on silica gel plates (Merck silica gel 60, f_{254}), and the spots were visualized with UV light (254 and 365 nm) or by charring the plate dipped in 5% H₂SO₄-MeOH or vanillin charring solution. ¹H and ¹³C NMR spectra were recorded in CDCl₃ or DMSO- d_6 solvent using TMS as the internal standard. HRMS (m/z) were measured using EI (magnetic sector, positive ion) and ESI (Q-TOF, positive ion) techniques. Infrared (IR) spectra were recorded on Fourier transform infrared spectroscopy, only intense peaks were reported.

Experimental Results. General Procedure for the Synthesis of **1a–g**. To a well-stirred solution of corresponding carbohydratederived enones (0.1 g, 1 equiv) in CCl₄/pyridine (1:1, 4 mL) at 0 °C was added dropwise iodine or bromine (2.1 equiv) dissolved in CCl₄/ pyridine (1:1, 4 mL) into it. The resulting reaction mixture was stirred for 2 h at ambient temperature (for iodination) or 0 °C for 1 h (for bromination). After completion of the reaction (TLC), the reaction mixture was extracted with DCM (20 mL), and washed successively with H₂O (10 mL), 1 N HCl (2 × 10 mL), and 20% aqueous Na₂S₂O₃ (10 mL) solution. The combined organic layer was dried over anhyd Na₂SO₄ and filtered, and the filtrate was concentrated under reduced pressure to get a residue. The crude residue was purified by silica gel column chromatography [230–400; eluent: ethyl acetate/*n*-hexane] to obtain **1a–g**. The analytical data of compounds **1a**, **1b**, **1c**, **1d**, and **1e** was exactly matched with those of the reported values.⁷c,^{8b,9}

General Procedure for the Synthesis of **2**. 2-Iodoenones/ 2-bromoenones **1** (0.05 g, 1.0 equiv), corresponding amidine salt (1.0 equiv), K_2CO_3 (3.0 equiv), and DMSO (1.0 mL) were added successively to a round-bottom flask under open air at room temperature, and the mixture was stirred at the same temperature employing time as mentioned. After completion of the reaction (TLC), saturated ammonium chloride solution was added, and the product was extracted with EtOAc. The combined organic layer was dried over anhydrous Na₂SO₄ and filtered, and the filtrate was concentrated under reduced pressure to get a residue. The crude residue was passed through a short pad of a silica gel column [230–400; eluent: ethyl acetate/ *n*-hexane] to obtain a residue. The residue was acetylated with Ac₂O (2.0 equiv), DMAP (catalytic), and py (0.5 mL) at 0 °C for 1 h. After completion of the reaction (TLC), saturated sodium bicarbonate solution was added at the same temperature, and the product was extracted with EtOAc. The combined organic layers were dried over anhydrous Na₂SO₄ and filtered, and the filtrate was concentrated under reduced pressure to get a residue. The crude residue was purified over silica gel column chromatography [230–400; eluent: ethyl acetate/ *n*-hexane] to obtain **2**.

General Procedure for the Synthesis of 2w-x. 1a or 1b (0.05 g, 1.0 equiv), corresponding amidine salt (1.0 equiv), K_2CO_3 (3.0 equiv), and DMSO (1.0 mL) were added successively in a round-bottom flask under open air at room temperature, and the mixtures were stirred at the same temperature employing time as mentioned. After completion of the reaction (TLC), saturated ammonium chloride solution was added, and the product was extracted with EtOAc. The combined organic layers were dried over anhydrous Na2SO4 and filtered, and the filtrate was concentrated under reduced pressure to get a residue. The crude residue was passed through a short pad of silica gel column [230-400; eluent: ethyl acetate/ n-hexane] to obtain a residue. The residue was treated with I2 (2.0 equiv), K2CO3 (2.0 equiv), and DMSO (1.0 mL) at room temperature for 1 h. After completion of the reaction (TLC), saturated sodium thiosulfate solution was added into it. The product was extracted with EtOAc, and the organic layer was washed with brine solution. The combined organic layers were dried over anhydrous Na2SO4 and filtered, and the filtrate was concentrated under reduced pressure to get a residue. The crude residue was purified over silica gel column chromatography [230-400; eluent: ethyl acetate/n-hexane] to obtain 2w-x.

General Procedure for the Synthesis of **3**. 2-Iodoenones/ 2-bromoenones **1** (0.05 g, 1.0 equiv), K_2CO_3 (3.0 equiv), DMSO (1.0 mL), and the corresponding 1,3-dicarbonyls **2** (1.0 equiv) were added successively to a round-bottom flask at ambient temperature under argon atmosphere, and the mixture was stirred at the same temperature employing time as mentioned. After completion of the reaction (TLC), saturated ammonium chloride solution was added, and the product was extracted with EtOAc. The combined organic layer was dried over anhydrous Na_2SO_4 and filtered, and the filtrate was concentrated under reduced pressure to get a residue. The crude residue was purified over silica gel column chromatography [230–400; eluent: ethyl acetate/*n*-hexane] to obtain **3**.

General Procedure for the Synthesis of 5a-b. To a well-stirred solution of 3z or 3b (0.05 g, 1 equiv) in dry pyridine (1.5 mL) at 0 °C was added dropwise benzoyl chloride (1.1 equiv/mmol) dissolved in pyridine (0.5 mL). The resulting reaction mixture was stirred at the same temperature for 30 min. After completion of the reaction (TLC), saturated sodium bicarbonate solution was added, and the product was extracted with EtOAc. The combined organic layer was dried over anhydrous Na2SO4 and filtered, and the filtrate was concentrated under reduced pressure to get a residue. The crude residue was passed through a short pad of silica gel column [230-400; eluent: ethyl acetate/n-hexane] to obtain a residue. The residue was treated with Et₃N (1.0 mL, neat) at room temperature for 16-36 h. After completion of the reaction (TLC), saturated ammonium chloride solution was added, and the product was extracted with EtOAc. The combined organic layers were dried over anhydrous Na2SO4 and filtered, and the filtrate was concentrated under reduced pressure to get a residue. The crude residue was purified over silica gel column chromatography [230-400; eluent: ethyl acetate/n-hexane] to obtain 5a-b.

(2R,3R)-2-(((tert-Butyldiphenylsilyl)oxy)methyl)-3-hydroxy-5iodo-2,3-dihydro-4H-pyran-4-one **1f**. Prepared according to the general procedure discussed above: $R_{\rm f} = 0.30$; eluent, EtOAc/ *n*-hexane (10%); isolated yield = 0.105 g, 76%; $[\alpha]_{\rm D}^{20} = +88$ (c =0.11 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): $\delta =$ 7.79 (s, 1 H), 7.69–7.72 (m, 4 H), 7.44–7.47 (m, 2 H), 7.40–7.42 (m, 4 H), 4.66 (dd, J = 1.8, 13.2 Hz, 1 H), 4.30 (dt, J = 2.4, 13.2 Hz, 1 H), 4.10 (dd, J = 1.8, 12.0 Hz, 1 H), 4.07 (dd, J = 3.0, 12.0 Hz, 1 H), 3.45 (d, J = 1.8 Hz, 1 H), 1.08 ppm (s, 9 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 190.3$, 167.0, 135.6 (4 CH), 132.9, 132.8, 129.8, 127.8 (3 CH), 127.7 (2 CH), 83.8, 70.1, 67.6, 61.9 (CH₂), 26.7 (3 CH₃), 19.4 ppm; IR (KBr): $\tilde{\nu}_{max} = 2930$, 2857, 1686, 1569, 1427, 1142, 1093, 1035, 968, 787, 742, 703, 610, 506 cm⁻¹; HRMS (ESI): m/z calcd for C₂₂H₂₅IO₄SiNa [M + Na]⁺: 531.0465; found: 531.0456.

(2*R*,35)-3-(*Benzyloxy*)-2-((*benzyloxy*)*methyl*)-5-*bromo-2,3-dihydro-4H-pyran-4-one* 1*g*. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (10%); isolated yield = 0.045 g, 72%; $[\alpha]_D^{20} = +4$ (c = 0.14 in MeOH); white solid; mp 127–130 °C. ¹H NMR (600 MHz, CDCl₃): $\delta = 7.71$ (s, 1 H), 7.34–7.37 (m, 3 H), 7.31–7.33 (m, 3 H), 7.28–7.30 (m, 4 H), 4.72 (d, J = 12.0 Hz, 1 H), 4.56–4.58 (m, 2 H), 4.50 (d, J = 12.0 Hz, 1 H), 4.48 (d, J = 12.0 Hz, 1 H), 3.94 (d, J = 2.4 Hz, 1 H), 3.90 (dd, J = 7.2, 10.8 Hz, 1 H), 3.76 ppm (dd, J = 6.0, 10.2 Hz, 1 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 182.6$, 161.5, 137.2, 136.5, 128.5 (2 CH), 128.5 (2 CH), 128.4 (2 CH), 128.2, 128.0, 127.8 (2 CH), 100.7, 81.4, 74.2, 73.7 (CH₂), 72.3 (CH₂), 67.1 (CH₂) ppm; IR (KBr): $\tilde{\nu}_{max} =$ 3039, 2876, 1684, 1574, 1364, 1272, 1089, 1032, 743, 697, 570 cm⁻¹; HRMS (ESI): m/z calcd for C₂₀H₁₉BrO₄Na [M + Na]⁺: 425.0365; found: 425.0369.

(2*R*,3*S*)-1,3-*Bis*(*benzyloxy*)-4-*oxo*-4-(2-*phenyl*-1*H*-*imidazol*-4-*yl*)*butan*-2-*yl acetate* **2a**. Prepared according to the general procedure discussed above: eluent, $R_f = 0.30$; EtOAc/*n*-hexane (35%); isolated yield = 0.045 g, 84%; $[\alpha]_D^{20} = -2$ (*c* = 0.065 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 11.08$ (br. s., 1 H), 8.13 (s, 1 H), 8.01–8.02 (m, 2 H), 7.40–7.46 (m, 3 H), 7.22–7.33 (m, 10 H), 5.45–5.47 (m, 1 H), 4.74 (d, *J* = 12.0 Hz, 1 H), 4.59 (d, *J* = 4.2 Hz, 1 H), 4.49 (d, *J* = 11.4 Hz, 1 H), 4.46 (d, *J* = 6.0 Hz, 2 H), 3.73 (dd, *J* = 6.6, 9.6 Hz, 1 H), 3.62 (dd, *J* = 5.4, 10.2 Hz, 1 H), 1.92 ppm (s, 3 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 189.2$, 170.1, 151.2, 140.0, 137.4, 136.5, 131.2, 130.3, 129.0 (2 CH), 128.5 (2 CH), 128.4, 128.3 (4 CH), 128.2 (2 CH), 127.7, 127.6 (2 CH), 126.4, 81.6, 73.4 (CH₂), 73.2 (CH₂), 72.2, 67.4 (CH₂), 20.7 ppm; IR (KBr): $\tilde{\nu}_{max} = 2925$, 2867, 1745, 1662, 1525, 1457, 1374, 1232, 1101, 1050, 745, 699 cm⁻¹; HRMS (ESI): *m/z* calcd for C₂₉H₂₈N₂O₃Na [*M* + Na]⁺: 507.1896; found: 507.1896. (2*R*,3*R*)-1,3-Bis(benzyloxy)-4-oxo-4-(2-phenyl-1H-imidazol-4-yl)butan-2-yl acetate **2b**. Prepared according to the general procedure discussed above: $R_f = 0.40$; eluent, EtOAc/*n*-hexane (35%); isolated yield = 0.039 g, 74%; $[\alpha]_D^{20} = +3$ (c = 0.12 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 10.49$ (br. s., 1 H), 8.11 (s, 1 H), 7.89–7.92 (m, 2 H), 7.47–7.49 (m, 3 H), 7.34 (m, 4 H), 7.25–7.28 (m, 6 H), 5.45 (q, J = 4.8 Hz, 1 H), 4.76 (d, J = 11.7 Hz, 1 H), 4.65 (d, J = 4.5 Hz, 1 H), 4.56 (d, J = 11.4 Hz, 1 H), 4.49 (m, 2 H), 3.80 (d, J =4.5 Hz, 2 H), 2.01 ppm (s, 3 H); ¹³C NMR (75 MHz, CDCl₃): $\delta =$ 187.7, 170.4, 150.6, 139.3, 137.6, 136.6, 131.0, 130.3, 129.0 (2 CH), 128.5 (2 CH), 128.5, 128.3 (2 CH), 128.2, 128.2 (2 CH), 127.6, 127.6 (2 CH), 126.2 (2 CH), 81.0, 73.3, 73.2 (CH₂), 73.1 (CH₂), 67.4 (CH₂), 20.9 ppm; IR (KBr): $\tilde{\nu}_{max} = 2924$, 1742, 1659, 1458, 1373, 1234, 1097, 698 cm⁻¹; HRMS (ESI): *m*/z calcd for C₂₉H₂₈N₂O₅Na [*M* + Na]⁺: 507.1896; found: 507.1884.

(*R*)-2-(*Benzyloxy*)-3-oxo-3-(2-phenyl-1H-imidazol-4-yl)propyl acetate **2c**. Prepared according to the general procedure discussed above: $R_f = 0.40$; eluent, EtOAc/*n*-hexane (40%); isolated yield = 0.047 g, 85%; $[\alpha]_D^{20} = +3$ (c = 0.17 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 11.11$ (br. s., 1 H), 8.15 (s, 1 H), 7.99–8.01 (m, 2 H), 7.44–7.45 (m, 3 H), 7.32–7.35 (m, 5 H), 4.75 (d, J = 11.4 Hz, 1 H), 4.62 (d, J = 11.4 Hz, 1 H), 4.53–4.57 (m, 2 H), 4.41–4.45 (m, 1 H), 2.01 ppm (s, 3 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 189.3$, 171.7, 152.1, 140.9, 137.5, 131.8, 131.5, 130.1 (2 CH), 129.7 (2 CH), 129.4, 129.3, 129.2 (2 CH), 127.3 (2 CH), 82.1, 73.8 (CH₂), 65.3 (CH₂), 21.8 ppm; IR (KBr): $\tilde{\nu}_{max} = 2924$, 1743, 1663, 1525, 1457, 1379, 1231, 1118, 1044, 699 cm⁻¹; HRMS (ESI): *m/z* calcd for C₂₁H₂₀N₂O₄Na [*M* + Na]⁺: 387.1321; found: 387.1317.

(25,35)-3-(benzyloxy)-4-oxo-4-(2-phenyl-1H-imidazol-4-yl)butan-2-yl acetate 2d. Prepared according to the general procedure discussed above: $R_{\rm f} = 0.40$; eluent, EtOAc/*n*-hexane (30%); isolated yield = 0.038 g, 69%; $[\alpha]_{\rm D}^{20} = -24$ (c = 0.10 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 10.65$ (br. s., 1 H), 8.13 (s, 1 H), 7.92–7.95 (m, 2 H), 7.46–7.51 (m, 3 H), 7.35 (m, 5 H), 5.27–5.35 (m, 1 H), 4.78 (d, J = 12.0 Hz, 1 H), 4.55 (d, J = 11.7 Hz, 1 H), 4.47 (d, J = 3.6 Hz, 1 H), 1.99 (s, 3 H), 1.33 ppm (d, J = 6.6 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 188.4$, 170.5, 151.1, 139.8, 136.8, 131.1, 130.4, 129.1 (2 CH), 128.6 (3 CH), 128.2, 128.1 (2 CH), 126.4 (2 CH), 83.8, 72.9 (CH₂), 71.4, 21.1, 15.3 ppm; IR (KBr): $\tilde{\nu}_{max} = 2927$, 1738, 1659, 1458, 1374, 1238, 1074, 700 cm⁻¹; HRMS (ESI): m/z calcd for C₂₂H₂₂N₂O₄Na [M + Na]⁺: 401.1478; found: 401.1491.

(25,3*R*)-3-(*Benzyloxy*)-4-oxo-4-(2-phenyl-1*H*-imidazol-4-yl)butan-2-yl acetate **2e**. Prepared according to the general procedure discussed above: $R_{\rm f} = 0.30$; eluent, EtOAc/*n*-hexane (35%); isolated yield = 0.048 g, 87%; $[\alpha]_{\rm D}^{20} = +18$ (c = 0.10 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 10.74$ (br. s., 1 H), 8.14 (s, 1 H), 7.96–7.97 (m, 2 H), 7.46–7.48 (m, 3 H), 7.33 (m, 5 H), 5.34 (quin, J = 6.0 Hz, 1 H), 4.77 (d, J = 11.7 Hz, 1 H), 4.50 (d, J = 11.7 Hz, 1 H), 4.22 (d, J = 4.8 Hz, 1 H), 1.94 (s, 3 H), 1.32 ppm (d, J = 6.3 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 189.4$, 170.3, 151.1, 140.0, 136.5, 131.2, 130.4, 129.0 (2 CH), 128.5 (3 CH), 128.2 (3 CH), 126.4 (2 CH), 85.1, 73.2 (CH₂), 70.4, 21.0, 16.5 ppm; IR (KBr): $\tilde{\nu}_{max} = 2928$, 1740, 1660, 1525, 1457, 1375, 1238, 1069, 751, 700 cm⁻¹; HRMS (ESI): *m*/z calcd for C₂₂H₂₂N₂O₄Na [*M* + Na]⁺: 401.1478; found: 401.1496.

(2*R*,3*S*)-1,3-*Bis*(*benzyloxy*)-4-(2-(4-*methoxyphenyl*)-1*H*-*imidazol*-4-*yl*)-4-oxobutan-2-*yl* acetate **2f**. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (40%); isolated yield = 0.044 g, 77%; $[\alpha]_D^{20} = -5$ (c = 0.10 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 10.33$ (br. s., 1 H), 8.06 (s, 1 H), 7.86 (d, J = 9.0 Hz, 2 H), 7.22–7.30 (m, 10 H), 6.98 (d, J = 8.7 Hz, 2 H), 5.41–5.47 (m, 1 H), 4.73 (d, J = 11.4 Hz, 1 H), 4.53 (d, J = 3.9 Hz, 1 H), 4.46–4.50 (m, 3 H), 3.85 (s, 3 H), 3.71 (dd, J = 6.3, 9.6 Hz, 1 H), 3.61 (dd, J = 5.7, 9.9 Hz, 1 H), 1.94 ppm (s, 3 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 188.8$, 170.1, 161.4, 151.6, 140.3, 137.5, 136.6, 131.1, 128.5 (2 CH), 128.4 (2 CH), 128.2 (2 CH), 128.4 (2 CH), 128.2 (2 CH), 128.2 (2 CH), 128.2 (2 CH), 128.4 (2 CH), 128.4 (2 CH), 81.4, 73.3 (CH₂), 73.3 (CH₂), 72.3, 67.5 (CH₂), 55.3, 20.8 ppm; IR (KBr): $\tilde{\nu}_{max} = 2926$, 1744, 1656, 1614, 1496, 1374, 1254, 1093, 1030, 839,

742, 699 cm⁻¹; HRMS (ESI): m/z calcd for $C_{30}H_{30}N_2O_6Na$ $[M + Na]^+$: 537.2002; found: 537.2015.

(2R,3R)-1,3-Bis(benzyloxy)-4-(2-(4-methoxyphenyl)-1H-imidazol-4-yl)-4-oxobutan-2-yl acetate 2g. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (40%); isolated yield = 0.045 g, 79%; $[\alpha]_{D}^{20} = +6$ (c = 0.11 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 10.85$ (br. s., 1 H), 8.10 (s, 1 H), 7.94 (d, J = 9.0 Hz, 2 H), 7.29-7.34 (m, 5 H), 7.24-7.25 (m, 2 H), 7.20–7.22 (m, 3 H), 6.96 (d, J = 9.0 Hz, 2 H), 5.42 (q, *J* = 4.8 Hz, 1 H), 4.74 (d, *J* = 12.0 Hz, 1 H), 4.68 (d, *J* = 4.8 Hz, 1 H), 4.51 (d, J = 11.4 Hz, 1 H), 4.47 (d, J = 12.0 Hz, 1 H), 4.43 (d, J = 12.0 Hz, 1 H), 3.83 (s, 3 H), 3.80 (dd, J = 5.4, 10.2 Hz, 1 H), 3.76 (dd, J = 4.2, 10.8 Hz, 1 H), 1.97 ppm (s, 3 H); ¹³C NMR (150 MHz, $CDCl_3$): $\delta = 187.4$, 170.4, 161.3, 151.0, 139.5, 137.6, 136.7, 130.8, 128.5 (2 CH), 128.3 (2 CH), 128.2, 128.1 (2 CH), 127.9 (2 CH), 127.6, 127.6 (2 CH), 121.2, 114.4 (2 CH), 80.9, 73.4, 73.2 (CH₂), 73.0 (CH₂), 67.5 (CH₂), 55.4, 20.9 ppm; IR (KBr): $\tilde{\nu}_{max} = 2927, 1742$, 1654, 1614, 1496, 1476, 1374, 1254, 1092, 1029, 838, 741, 699 cm⁻¹; HRMS (ESI): m/z calcd for $C_{30}H_{30}N_2O_6Na [M + Na]^+$: 537.2002; found: 537.2010.

(25,35)-3-(Benzyloxy)-4-(2-(4-methoxyphenyl)-1H-imidazol-4-yl)-4-oxobutan-2-yl acetate **2h**. Prepared according to the general procedure discussed above: $R_f = 0.40$; eluent, EtOAc/*n*-hexane (40%); isolated yield = 0.045 g, 76%; $[\alpha]_D^{20} = -7$ (c = 0.10 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 10.55$ (br. s., 1 H), 8.13 (s, 1 H), 7.91 (d, J = 8.7 Hz, 2 H), 7.36 (m, 5 H), 7.00 (d, J = 9.0 Hz, 2 H), 5.28–5.36 (m, 1 H), 4.80 (d, J = 11.7 Hz, 1 H), 4.55 (d, J = 11.7 Hz, 1 H), 4.48 (d, J = 3.6 Hz, 1 H), 3.88 (s, 3 H), 2.01 (s, 3 H), 1.35 ppm (d, J = 6.6 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 188.1$, 170.4, 161.4, 151.5, 140.2, 136.9, 130.9, 128.5 (2 CH), 128.2 (2 CH), 128.1 (3 CH), 121.2, 114.4 (2 CH), 83.6, 72.8 (CH₂), 71.4, 55.3, 21.1, 15.3 ppm; IR (KBr): $\tilde{\nu}_{max} = 2933$, 1740, 1656, 1615, 1497, 1375, 1252, 1181, 1070, 1028, 840, 744, 699 cm⁻¹; HRMS (ESI): *m*/z calcd for $C_{23}H_{24}N_2O_3Na [M + Na]^+$: 431.1583; found: 431.1567.

(25,3*R*)-3-(*Benzyloxy*)-4-(2-(4-methoxyphenyl)-1*H*-imidazol-4-yl)-4-oxobutan-2-yl acetate 2*i*. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (40%); isolated yield = 0.051 g, 86%; $[\alpha]_D^{20} = +1$ (c = 0.11 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 11.28$ (br. s., 1 H), 8.14 (s, 1 H), 8.03 (d, J = 8.4 Hz, 2 H), 7.29–7.34 (m, 5 H), 6.96 (d, J = 9.0 Hz, 2 H), 5.34–5.38 (m, 1 H), 4.77 (d, J = 12.0 Hz, 1 H), 4.28 (d, J = 4.8 Hz, 1 H), 3.84 (s, 3 H), 1.94 (s, 3 H), 1.31 ppm (d, J = 6.6 Hz, 3 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 189.0$, 170.3, 161.4, 151.4, 140.2, 136.6, 131.0, 128.5 (2 CH), 128.2, 128.1 (2 CH), 128.1 (2 CH), 121.1, 114.4 (2 CH), 84.8, 73.1 (CH₂), 70.4, 55.3, 21.0, 16.5 ppm; IR (KBr): $\tilde{\nu}_{max} = 2932$, 1738, 1654, 1614, 1497, 1477, 1374, 1252, 1181, 1078, 1030, 838, 744, 699 cm⁻¹; HRMS (ESI): *m*/z calcd for C₂₃H₂₄N₂O₅Na [*M* + Na]⁺: 431.1583; found: 431.1573.

(2*R*,3*S*)-1,3-*Bis*(*benzyloxy*)-4-(2-(4-*chlorophenyl*)-1*H*-*imidazol*-4yl)-4-oxobutan-2-yl acetate **2***j*. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (35%); isolated yield = 0.041 g, 72%; $[\alpha]_D^{20} = -4$ (c = 0.13 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 10.84$ (br. s., 1 H), 8.10 (s, 1 H), 7.91 (d, J = 8.1 Hz, 2 H), 7.45 (d, J = 8.4 Hz, 2 H), 7.28–7.32 (m, 10 H), 5.42–5.47 (m, 1 H), 4.73 (d, J = 11.7 Hz, 1 H), 4.57 (d, J = 3.9 Hz, 1 H), 4.49–4.53 (m, 3 H), 3.73 (dd, J = 7.2, 9.6 Hz, 1 H), 3.63 (dd, J = 5.7, 9.9 Hz, 1 H), 1.95 ppm (s, 3 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 189.5$, 170.1, 150.3, 140.1, 137.4, 136.5, 136.4, 131.4, 129.3 (2 CH), 128.6 (2 CH), 128.4 (4 CH), 128.3 (2 CH), 127.8 (2 CH), 127.7 (2 CH), 127.0, 81.5, 73.5 (CH₂), 73.3 (CH₂), 72.3, 67.3 (CH₂), 20.8 ppm; IR (KBr): $\tilde{\nu}_{max} = 2925$, 2866, 1745, 1662, 1480, 1425, 1373, 1231, 1095, 1050, 738, 698 cm⁻¹; HRMS (ESI): *m/z* calcd for C₂₉H₂₇ClN₂O₅Na [*M* + Na]⁺: 541.1506; found: 541.1506.

(2R,3R)-1,3-Bis(benzyloxy)-4-(2-(4-chlorophenyl)-1H-imidazol-4yl)-4-oxobutan-2-yl acetate 2k. Prepared according to the general procedure discussed above: $R_{\rm f} = 0.30$; eluent, EtOAc/*n*-hexane (%); isolated yield = 0.029 g, 51%; $[\alpha]_{\rm D}^{20} = +3$ (c = 0.13 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 10.73$ (br. s., 1 H), 8.11 (s, 1 H), 7.87 (d, J = 8.4 Hz, 2 H), 7.44 (d, J = 8.1 Hz, 2 H), 7.23–7.34 (m, 10 H), 5.40–5.45 (m, 1 H), 4.76 (d, J = 11.4 Hz, 1 H), 4.66 (d, J = 4.2 Hz, 1 H), 4.55 (d, J = 11.7 Hz, 1 H), 4.48 (s, 2 H), 3.80 (d, J = 5.4 Hz, 2 H), 2.01 ppm (s, 3 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 188.0$, 170.4, 149.9, 139.6, 137.5, 136.5, 136.4, 131.2, 129.3 (2 CH), 128.6 (2 CH), 128.3 (4 CH), 128.2 (2 CH), 127.7 (2 CH), 127.6 (2 CH), 127.0, 80.9, 73.4, 73.3 (CH₂), 73.2 (CH₂), 67.4 (CH₂), 20.9 ppm; IR (KBr): $\tilde{v}_{max} = 2925$, 1742, 1659, 1462, 1372, 1234, 1094, 837, 738, 699 cm⁻¹; HRMS (ESI): m/z calcd for C₂₉H₂₇ClN₂O₅Na [M + Na]⁺: 541.1506; found: 541.1504.

(25,35)-3-(Benzyloxy)-4-(2-(4-chlorophenyl)-1H-imidazol-4-yl)-4oxobutan-2-yl acetate **2l**. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (30%); isolated yield = 0.040 g, 68%; $[\alpha]_D^{20} = -8$ (c = 0.11 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 11.00$ (br. s., 1 H), 8.14 (s, 1 H), 7.94 (d, J = 8.4 Hz, 2 H), 7.43 (d, J = 8.4 Hz, 2 H), 7.34 (m, 5 H), 5.26–5.34 (m, 1 H), 4.77 (d, J = 11.7 Hz, 1 H), 4.54 (d, J =11.7 Hz, 1 H), 4.50 (d, J = 4.2 Hz, 1 H), 1.99 (s, 3 H), 1.33 ppm (d, J =6.6 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 188.1$, 170.1, 149.9, 139.6, 136.3, 136.1, 130.9, 128.9 (2 CH), 128.2 (2 CH), 127.9, 127.8 (2 CH), 127.4 (2 CH), 126.7, 83.2, 72.6 (CH₂), 71.0, 20.7, 14.8 ppm; IR (KBr): $\tilde{\nu}_{max} = 2927$, 1738, 1658, 1478, 1464, 1373, 1238, 1089, 836, 737, 698 cm⁻¹; HRMS (ESI): *m*/*z* calcd for C₂₂H₂₁ClN₂O₄Na [*M* + Na]⁺: 435.1088; found: 435.1080.

(25,3*R*)-3-(*Benzyloxy*)-4-(2-(4-*chlorophenyl*)-1*H*-*imidazol*-4-*y*])-4oxobutan-2-yl acetate **2m**. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (35%); isolated yield = 0.047 g, 79%; $[\alpha]_D^{20} = +1$ (c = 0.10 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 10.71$ (br. s., 1 H), 8.11 (s, 1 H), 7.89 (d, J = 8.7 Hz, 2 H), 7.44 (d, J = 8.7 Hz, 2 H), 7.32– 7.33 (m, 5 H), 5.29–5.37 (m, 1 H), 4.75 (d, J = 11.7 Hz, 1 H), 4.51 (d, J = 11.7 Hz, 1 H), 4.20 (d, J = 5.1 Hz, 1 H), 1.94 (s, 3 H), 1.32 ppm (d, J = 6.6 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 189.6$, 170.4, 150.4, 140.1, 136.6, 136.4, 131.4, 129.3 (2 CH), 128.6 (2 CH), 128.4, 128.2 (2 CH), 127.9 (2 CH), 127.0, 84.8, 73.3 (CH₂), 70.4, 21.0, 16.6 ppm; IR (KBr): $\tilde{\nu}_{max} = 2927$, 1741, 1660, 1481, 1425, 1374, 1237, 1090, 1070, 838, 738, 697 cm⁻¹; HRMS (ESI): m/z calcd for C₂₂H₂₁ClN₂O₄Na [*M*+Na]⁺: 435.1088; found: 435.1090.

(2*R*,3*S*)-1,3-*Bis*(*benzyloxy*)-4-(2-(*tert-butyl*)-1*H-imidazol-4-yl*)-4oxobutan-2-yl acetate **2n**. Prepared according to the general procedure discussed above: $R_f = 0.40$; eluent, EtOAc/*n*-hexane (40%); isolated yield = 0.038 g, 74%; $[\alpha]_D^{20} = -4$ (c = 0.13 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 9.74$ (br. s., 1 H), 7.92 (s, 1 H), 7.23–7.32 (m, 10 H), 5.37–5.43 (m, 1 H), 4.70 (d, J =11.7 Hz, 1 H), 4.43–4.49 (m, 4 H), 3.68 (dd, J = 6.3, 9.9 Hz, 1 H), 3.59 (dd, J = 5.7, 9.6 Hz, 1 H), 1.94 (s, 3 H), 1.37 ppm (s, 9 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 188.6$, 170.1, 161.1, 138.3, 137.6, 136.6, 129.7, 128.5 (2 CH), 128.3 (2 CH), 128.1 (CH), 128.1 (2 CH), 127.7, 127.6 (2 CH), 81.5, 73.3 (CH₂), 73.2 (CH₂), 72.0, 67.4 (CH₂), 33.1, 29.0 (3 CH₃), 20.8 ppm; IR (KBr): $\tilde{\nu}_{max} = 2966$, 2927, 2870, 1745, 1660, 1532, 1371, 1231, 1106, 1051, 742, 699 cm⁻¹; HRMS (ESI): *m*/z calcd for C₂₇H₃₂N₂O₅Na [*M* + Na]⁺: 487.2209; found: 487.2203.

 $(2R, 3\dot{R})$ -1,3-Bis(benzyloxy)-4-(2-(tert-butyl)-1H-imidazol-4-yl)-4oxobutan-2-yl acetate **20**. Prepared according to the general procedure discussed above: $R_{\rm f} = 0.40$; eluent, EtOAc/*n*-hexane (35%); isolated yield = 0.039 g, 76%; $[\alpha]_{\rm D}^{20} = +1$ (c = 0.15 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 9.79$ (br. s., 1 H), 7.95 (s, 1 H), 7.28–7.32 (m, 10 H), 5.42 (br. s., 1 H), 4.72 (d, J = 11.1 Hz, 1 H), 4.60 (br. s., 1 H), 4.49–4.53 (m, 3 H), 3.77 (br. s., 2 H), 1.99 (s, 3 H), 1.38 ppm (s, 9 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 187.5$, 170.2, 161.1, 138.0, 137.8, 136.7, 129.7, 128.5 (2 CH), 128.3 (2 CH), 128.1, 128.1 (2 CH), 127.6, 127.5 (2 CH), 80.9, 73.2 (1 CH and 1 CH₂), 73.0 (CH₂), 67.6 (CH₂), 33.1, 29.1 (3 CH₃), 20.9 ppm; IR (KBr): $\tilde{\nu}_{max} =$ 2965, 2928, 2870, 1743, 1662, 1532, 1457, 1370, 1234, 1110, 741, 699 cm⁻¹; HRMS (ESI): m/z calcd for C₂₇H₃₂N₂O₅Na [M + Na]⁺: 487.2209; found: 487.2213.

(*R*)-2-(Benzyloxy)-3-(2-(tert-butyl)-1H-imidazol-4-yl)-3-oxopropyl acetate **2p**. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (40%); isolated yield = 0.028 g, 53%; $[\alpha]_D^{20} = +1$ (c = 0.12 in MeOH); colorless gum.

¹H NMR (600 MHz, CDCl₃): δ = 9.93 (br. s., 1 H), 7.96 (s, 1 H), 7.31–7.36 (m, 5 H), 4.72 (d, J = 12.0 Hz, 1 H), 4.57 (d, J = 11.4 Hz, 1 H), 4.46–4.49 (m, 2 H), 4.35–4.39 (m, 1 H), 2.01 (s, 3 H), 1.39 ppm (s, 9 H); ¹³C NMR (150 MHz, CDCl₃): δ = 189.0, 171.6, 162.4, 139.5, 137.6, 130.4, 129.6 (2 CH), 129.3, 129.1 (2 CH), 82.0, 73.7 (CH₂), 65.3 (CH₂), 34.2, 30.1 (3 CH₃), 21.8 ppm; IR (KBr): $\tilde{\nu}_{max} = 2965$, 2928, 1744, 1661, 1533, 1458, 1372, 1228, 1111, 1045, 742, 699 cm⁻¹; HRMS (ESI): *m*/*z* calcd for C₁₉H₂₄N₂O₄Na [*M* + Na]⁺: 367.1634; found: 367.1637.

(25,35)-3-(*Benzyloxy*)-4-(2-(*tert-butyl*)-1*H-imidazol-4-yl*)-4-oxo*butan-2-yl acetate* **2q**. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (40%); isolated yield = 0.039 g, 75%; $[\alpha]_D^{20} = -7$ (c = 0.11 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 10.09$ (br. s, 1 H), 7.98 (s, 1 H), 7.29–7.36 (m, 5 H), 5.24–5.28 (m, 1 H), 4.75 (d, J = 12.0 Hz, 1 H), 4.50 (d, J = 11.4 Hz, 1 H), 4.42 (d, J = 4.2 Hz, 1 H), 1.97 (s, 3 H), 1.40 (s, 9 H), 1.31 ppm (d, J = 6.6 Hz, 3 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 188.0$, 170.3, 161.2, 138.4, 136.8, 129.7, 128.5 (2 CH), 128.1, 128.0 (2 CH), 83.7, 72.8 (CH₂), 71.3, 33.1, 29.1 (3 CH₃), 21.1, 15.1 ppm; IR (KBr): $\tilde{v}_{max} = 2969$, 1739, 1661, 1532, 1371, 1240, 1072, 748 cm⁻¹; HRMS (ESI): *m*/*z* calcd for C₂₀H₂₆N₂O₄Na [*M* + Na]⁺: 381.1791; found: 381.1778.

(25,3*R*)-3-(*Benzyloxy*)-4-(2-(*tert-butyl*)-1*H-imidazol-4-yl*)-4-oxo*butan-2-yl acetate* **2r**. Prepared according to the general procedure discussed above: $R_f = 0.40$; eluent, EtOAc/*n*-hexane (40%); isolated yield = 0.046 g, 88%; $[\alpha]_D^{20} = +1$ (c = 0.11 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 9.84$ (br. s., 1 H), 7.96 (s, 1 H), 7.29–7.38 (m, 5 H), 5.29 (quin, J = 6.0 Hz, 1 H), 4.73 (d, J = 11.7 Hz, 1 H), 4.46 (d, J = 11.7 Hz, 1 H), 4.15 (d, J = 4.8 Hz, 1 H), 1.94 (s, 3 H), 1.39 (s, 9 H), 1.28 ppm (d, J = 6.6 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 189.0$, 170.2, 161.3, 138.5, 136.6, 129.8, 128.5 (2 CH), 128.1, 128.0 (2 CH), 85.3, 73.1 (CH₂), 70.3, 33.2, 29.1 (3 CH₃), 21.0, 16.5 ppm; IR (KBr): $\tilde{\nu}_{max} = 2968$, 2931, 1741, 1658, 1532, 1372, 1238, 1070, 742, 698 cm⁻¹; HRMS (ESI): *m/z* calcd for C₂₀H₂₆N₂O₄Na [*M*+Na]⁺: 381.1791; found: 381.1800.

(2R,3S)-1,3-Bis(benzyloxy)-4-(2-cyclopropyl-1H-imidazol-4-yl)-4oxobutan-2-yl acetate 2s. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/n-hexane (40%); isolated yield = 0.032 g, 64%; $[\alpha]_D^{20} = -6$ (c = 0.10 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): δ = 10.49 (br. s., 1 H), 7.90 (s, 1 H), 7.29-7.32 (m, 4 H), 7.26-7.28 (m, 4 H), 7.22 (d, J = 7.2 Hz, 2 H), 5.39–5.41 (m, 1 H), 4.71 (d, J = 12.0 Hz, 1 H), 4.49 (d, *J* = 3.6 Hz, 1 H), 4.42–4.47 (m, 3 H), 3.68 (dd, *J* = 6.6, 10.2 Hz, 1 H), 3.58 (dd, J = 6.0, 9.6 Hz, 1 H), 1.97-2.00 (m, 1 H), 1.94 (s, 3 H), 1.08 (m, 2 H), 1.03–1.06 ppm (m, 2 H); ¹³C NMR (150 MHz, CDCl₃): δ = 189.1, 171.2, 157.2, 140.1, 138.6, 137.6, 131.0, 129.5 (2 CH), 129.4 (2 CH), 129.2, 129.2 (2 CH), 128.7, 128.6 (2 CH), 82.4, 74.2 (CH₂), 74.2 (CH₂), 73.1, 68.6 (CH₂), 21.8, 10.3, 10.0 ppm (2 CH₂); IR (KBr): $\tilde{\nu}_{max} = 2925$, 2868, 1744, 1657, 1526, 1372, 1232, 1105, 1054, 742, 699 cm⁻¹; HRMS (ESI): m/z calcd for $C_{26}H_{28}N_2O_5N_4$ $[M + Na]^+$: 471.1896; found: 471.1902.

(2*R*,3*R*)-1,3-Bis(benzyloxy)-4-(2-cyclopropyl-1H-imidazol-4-yl)-4oxobutan-2-yl acetate **2t**. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (40%); isolated yield = 0.024 g, 49%; $[\alpha]_D^{20} = +1$ (c = 0.1 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 10.01$ (br. s., 1 H), 7.89 (s, 1 H), 7.28–7.32 (m, 10 H), 5.40 (m, 1 H), 4.72 (d, J =11.1 Hz, 1 H), 4.57 (m, 1 H), 4.48 (m, 3 H), 3.77 (m, 2 H), 1.99 (s, 3 H), 1.93–1.95 (m, 1 H), 1.08 ppm (m, 4 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 187.0$, 170.2, 156.0, 138.8, 137.7, 136.8, 129.9, 128.5 (2 CH), 128.3 (2 CH), 128.1, 128.0 (2 CH), 127.6, 127.5 (2 CH), 80.7, 73.2, 73.2 (CH₂) 73.0 (CH₂), 67.6 (CH₂), 20.9, 9.3, 8.9 ppm (2 CH₂); IR (KBr): $\tilde{\nu}_{max} = 2924$, 1742, 1657, 1522, 1371, 1234, 1107, 740, 699 cm⁻¹; HRMS (ESI): *m*/z calcd for C₂₆H₂₈N₂O₅Na [*M* + Na]⁺: 471.1896; found: 471.1887.

(25,35)-3-(Benzyloxy)-4-(2-cyclopropyl-1H-imidazol-4-yl)-4-oxobutan-2-yl acetate **2u**. Prepared according to the general procedure discussed above: $R_{\rm f} = 0.30$; eluent, EtOAc/*n*-hexane (43%); isolated yield = 0.021 g, 43%; $[\alpha]_{\rm D}^{20} = -8$ (*c* = 0.11 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 10.73$ (br. s., 1 H), 7.94 (s, 1 H), 7.29–7.36 (m, 5 H), 5.22–5.29 (m, 1 H), 4.74 (d, J = 12.0 Hz, 1 H), 4.47 (d, J = 12.0 Hz, 1 H), 4.40 (br. s., 1 H), 1.98–2.06 (m, 1 H), 1.96 (s, 3 H), 1.29 (d, J = 6.6 Hz, 3 H), 1.04–1.10 ppm (m, 4 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 188.6$, 171.3, 157.2, 140.1, 137.9, 130.9, 129.5 (2 CH), 129.1, 128.9 (2 CH), 84.7, 73.8 (CH₂), 72.4, 22.1, 16.2, 10.3, 9.9 (2 CH₂) ppm; IR (KBr): $\tilde{\nu}_{max} = 2926$, 1738, 1656, 1523, 1239, 1070 cm⁻¹; HRMS (ESI): m/z calcd for C₁₉H₂₂N₂O₄Na [M + Na]⁺: 365.1478; found: 365.1470.

(25,3*R*)-3-(*Benzyloxy*)-4-(2-cyclopropyl-1*H*-imidazol-4-yl)-4-oxobutan-2-yl acetate **2v**. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (40%); isolated yield = 0.031 g, 63%; $[\alpha]_D^{20} = +4$ (c = 0.11 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 10.05$ (br. s., 1 H), 7.91 (s, 1 H), 7.30–7.32 (m, 5 H), 5.27 (quin, J = 6.0 Hz, 1 H), 4.73 (d, J = 11.7 Hz, 1 H), 4.43 (d, J = 11.7 Hz, 1 H), 4.13 (d, J = 4.8 Hz, 1 H), 1.96–2.01 (m, 1 H), 1.94 (s, 3 H), 1.26 (d, J = 6.6 Hz, 3 H), 1.07–1.10 ppm (m, 4 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 188.5$, 170.3, 156.5, 139.4, 136.7, 130.0, 128.5 (2 CH), 128.1, 128.0 (2 CH), 84.9, 73.0 (CH₂), 70.4, 21.0, 16.5, 9.3, 9.0 (2 CH₂) ppm; IR (KBr): $\tilde{v}_{max} = 2927$, 1740, 1656, 1526, 1374, 1238, 1069, 747, 699 cm⁻¹; HRMS (ESI): *m*/z calcd for C₁₉H₂₂N₂O₄Na [*M* + Na]⁺: 365.1478; found: 365.1460.

(25,3R)-2,4-Bis(benzyloxy)-3-hydroxy-1-(5-iodo-2-phenyl-1H-imidazol-4-yl)butan-1-one **2w**. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (35%); isolated yield = 0.039 g, 62%; $[\alpha]_D^{20} = -9$ (c = 0.12 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 11.15$ (br. s., 1 H), 7.64–7.65 (m, 2 H), 7.40–7.43 (m, 1 H), 7.35–7.38 (m, 2 H), 7.27–7.34 (m, 8 H), 7.23–7.24 (m, 2 H), 4.59 (d, J = 10.8 Hz, 1 H), 4.56 (d, J = 12.0 Hz, 1 H), 4.51–4.55 (m, 2 H), 4.50 (d, J = 3.0 Hz, 1 H), 4.25–4.26 (m, 1 H), 3.72 (dd, J = 6.6, 9.6 Hz, 1 H), 3.65 (dd, J = 5.4, 10.2 Hz, 1 H), 2.95 ppm (d, J = 4.2 Hz, 1 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 188.3$, 150.7, 137.4, 136.1, 130.5, 130.4, 128.9 (2 CH), 128.7 (2 CH), 128.6, 128.5 (4 CH), 127.9, 127.8 (2 CH), 127.7, 125.9 (2 CH), 94.4, 84.1, 73.6 (2 CH₂), 71.3, 70.6 (CH₂) ppm; IR (KBr): $\tilde{\nu}_{max} = 2924$, 2858, 1661, 1591, 1458, 1385, 1236, 1074, 741, 698 cm⁻¹; HRMS (ESI): *m*/z calcd for C₂₇H₂₅IN₂O₄Na [*M* + Na]⁺: 591.0757; found: 591.0777.

(2R,3R)-2,4-Bis(benzyloxy)-3-hydroxy-1-(5-iodo-2-phenyl-1H-imidazol-4-yl)butan-1-one 2x. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/n-hexane (35%); isolated yield = 0.040 g, 63%; $[\alpha]_{D}^{20} = -1$ (c = 0.12 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): δ = 11.16 (br. s., 1 H), 7.64 (d, J = 7.2 Hz, 2 H), 7.40 (t, J = 7.2 Hz, 1 H), 7.35 (t, J = 7.8 Hz, 2 H), 7.30-7.31 (m, 3 H), 7.23-7.29 (m, 7 H), 4.63 (d, J = 10.8 Hz, 2 H), 4.59 (d, J = 11.4 Hz, 1 H), 4.49 (s, 2 H), 4.34 (m, 1 H), 3.69 (dd, J = 4.2, 10.2 Hz, 1 H), 3.60 (dd, J = 6.6, 9.6 Hz, 1 H), 3.01 ppm (br. s., 1 H); ¹³C NMR (150 MHz, CDCl₃): δ = 187.8, 150.6, 137.3, 136.3, 131.0, 130.4, 128.9 (2 CH), 128.8 (2 CH), 128.5, 128.4 (2 CH), 128.4 (2 CH), 127.9, 127.8 (2 CH), 127.6, 125.9 (2 CH), 94.6, 84.4, 73.6 (CH₂), 73.4 (CH₂), 71.7, 70.0 (CH₂) ppm; IR (KBr): $\tilde{\nu}_{\text{max}} = 2924, 2860, 1661, 1496, 1459, 1233, 1093, 745, 698 \text{ cm}^{-1};$ HRMS (ESI): m/z calcd for $C_{27}H_{25}IN_2O_4Na [M + Na]^+$: 591.0757; found: 591.0770.

Ethyl 5-((2R,3S)-2-(benzyloxy)-3-hydroxybutanoyl)-2-methylfuran-3-carboxylate **3a**. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (22%); isolated yield = 0.039 g, 78%; $[\alpha]_D^{20} = +8$ (c = 0.10 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 7.67$ (s, 1 H), 7.30–7.36 (m, 5 H), 4.72 (d, J = 11.4 Hz, 1 H), 4.47 (d, J = 11.4 Hz, 1 H), 4.32 (q, J = 7.8, 14.4 Hz, 2 H), 4.14 (d, J = 6.0 Hz, 1 H), 4.07–4.12 (m, 1 H), 2.69 (s, 3 H), 2.62 (d, J = 4.8 Hz, 1 H), 1.36 (t, J = 7.2 Hz, 3 H), 1.19 ppm (d, J = 6.0 Hz, 3 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 188.6$, 165.2, 163.7, 149.7, 137.6, 129.6 (2 CH), 129.4 (2 CH), 129.4, 122.5, 117.3, 88.2, 74.1 (CH₂), 69.9, 61.8 (CH₂), 19.7, 15.3, 15.3 ppm; IR (KBr): $\tilde{\nu}_{max} = 2927$, 1719, 1668, 1592, 1528, 1432, 1241, 1097 cm⁻¹; HRMS (ESI): *m*/*z* calcd for C₁₉H₂₂O₆Na [*M* + Na]⁺: 369.1314; found: 369.1321.

Benzyl 5-((2R,3S)-2-(benzyloxy)-3-hydroxybutanoyl)-2-methylfuran-3-carboxylate **3b**. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (20%); isolated yield = 0.043 g, 73%; $[\alpha]_D^{20} = +4$ (c = 0.25 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 7.69$ (s, 1 H), 7.42 (m, 5 H), 7.32 (m, 5 H), 5.32 (s, 2 H), 4.72 (d, J = 11.4 Hz, 1 H), 4.48 (d, J = 11.4Hz, 1 H), 4.07–4.16 (m, 2 H), 2.71 (s, 3 H), 2.60 (d, J = 4.2 Hz, 1 H), 1.20 ppm (d, J = 6.0 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 187.6$, 164.4, 162.5, 148.8, 136.5, 135.5, 128.6 (2 CH), 128.5 (2 CH), 128.4, 128.3 (2 CH), 128.3 (2 CH), 128.1, 121.2, 115.9, 87.1, 73.1 (CH₂), 68.8, 66.5 (CH₂), 18.7, 14.3 ppm; IR (KBr): $\tilde{\nu}_{max} = 2926$, 1721, 1670, 1592, 1529, 1454, 1235, 1094, 748, 700 cm⁻¹; HRMS (ESI): m/z calcd for C₂₄H₂₄O₆Na [M + Na]⁺: 431.1471; found: 431.1462.

Ethyl 5-((2*R*,35)-2-(*benzyloxy*)-3-*hydroxybutanoyl*)-2-*phenylfuran*-3-*carboxylate* 3*c*. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (20%); isolated yield = 0.040 g, 67%; $[\alpha]_D^{20} = +1$ (*c* = 0.2 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 8.07-8.09$ (m, 2 H), 7.82 (s, 1 H), 7.46-7.50 (m, 3 H), 7.31-7.37 (m, 5 H), 4.76 (d, *J* = 11.4 Hz, 1 H), 4.53 (d, *J* = 11.4 Hz, 1 H), 4.35 (dd, *J* = 0.6, 7.2 Hz, 1 H), 4.33 (dd, *J* = 1.2, 7.2 Hz, 1 H), 4.25 (d, *J* = 6.6 Hz, 1 H), 4.17 (quin, *J* = 6.6 Hz, 1 H), 2.68 (br. s., 1 H), 1.36 (t, *J* = 7.2 Hz, 3 H), 1.24 ppm (d, *J* = 6.6 Hz, 3 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 187.8$, 162.4, 160.8, 148.7, 136.6, 130.9, 129.1 (2 CH), 128.6 (2 CH), 128.4 (2 CH), 128.4, 128.3 (2 CH), 128.2, 122.9, 116.0, 87.2, 73.2 (CH₂), 68.8, 61.1 (CH₂), 18.8, 14.2 ppm; IR (KBr): $\tilde{v}_{max} = 2979$, 2929, 1722, 1668, 1574, 1525, 1484, 1218, 1101, 763, 696 cm⁻¹; HRMS (ESI): *m*/*z* calcd for C₂₄H₂₄O₆Na [*M* + Na]⁺: 431.1471; found: 431.1489.

Ethyl 5-((2R,3S)-2-(benzyloxy)-3-hydroxybutanoyl)-2-(4chlorophenyl)furan-3-carboxylate **3d**. Prepared according to the general procedure discussed above: $R_f = 0.40$; eluent, EtOAc/*n*-hexane (25%); isolated yield = 0.026 g, 40%; $[\alpha]_D^{20} = -4$ (c = 0.33 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 8.08$ (d, J =8.4 Hz, 2 H), 7.82 (s, 1 H), 7.46 (d, J = 8.4 Hz, 2 H), 7.33–7.36 (m, 5 H), 4.76 (d, J = 11.4 Hz, 1 H), 4.54 (d, J = 11.4 Hz, 1 H), 4.35 (q, J = 7.2, 14.4 Hz, 2 H), 4.22 (d, J = 6.0 Hz, 1 H), 4.15–4.17 (m, 1 H), 2.64 (br. s., 1 H), 1.37 (t, J = 6.6 Hz, 3 H), 1.24 ppm (d, J = 6.6 Hz, 3 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 187.8$, 162.2, 159.5, 148.7, 137.1, 136.5, 130.4 (2 CH), 128.7 (2 CH), 128.6 (2 CH), 128.4 (2 CH), 128.4, 126.6, 122.9, 116.2, 87.3, 73.2 (CH₂), 68.8, 61.3 (CH₂), 18.7, 14.2 ppm; IR (KBr): $\tilde{\nu}_{max} = 2923$, 2853, 1722, 1668, 1585, 1479, 1219, 1095, 838, 698 cm⁻¹; HRMS (ESI): *m*/*z* calcd for C₂₄H₂₃ClO₆Na [*M* + Na]⁺: 465.1081; found: 465.1098.

Methyl 5-((2*R*,35)-2-(*benzyloxy*)-3-hydroxybutanoyl)-2-methoxyfuran-3-carboxylate 3e. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (40%); isolated yield = 0.020 g, 40%; $[\alpha]_D^{20} = +1$ (c = 0.12 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 7.75$ (s, 1 H), 7.31–7.37 (m, 5 H), 4.72 (d, J = 11.4 Hz, 1 H), 4.47 (d, J = 11.4 Hz, 1 H), 4.27 (s, 3 H), 4.04–4.08 (m, 2 H), 3.83 (s, 3 H), 2.67 (br. s., 1 H), 1.18 ppm (d, J =5.4 Hz, 3 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 185.5$, 164.2, 162.1, 141.1, 136.5, 128.6 (2 CH), 128.4 (2 CH), 128.3, 125.1, 94.4, 87.1, 73.0 (CH₂), 69.0, 58.6, 51.7, 18.6 ppm; IR (KBr): $\tilde{v}_{max} = 2928$, 1718, 1657, 1597, 1544, 1409, 1243, 1100, 776 cm⁻¹; HRMS (ESI): m/zcalcd for C₁₈H₂₀O₇Na [M + Na]⁺: 371.1107; found: 371.1126.

Ethyl 5-*i*(25,35)-2-*i*(benzyloxy)-3-hydroxybutanoyl)-2-methylfuran-3-carboxylate **3f**. Prepared according to the general procedure discussed above: $R_f = 0.32$; eluent, EtOAc/*n*-hexane (20%); isolated yield = 0.040 g, 80%; $[\alpha]_D^{20} = -1$ (*c* = 0.12 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 7.66$ (s, 1 H), 7.30–7.36 (m, 5 H), 4.73 (d, *J* = 11.4 Hz, 1 H), 4.47 (d, *J* = 11.4 Hz, 1 H), 4.34 (d, *J* = 4.8 Hz, 1 H), 4.31 (q, *J* = 7.2, 14.4 Hz, 2 H), 4.18–4.21 (m, 1 H), 2.68 (s, 3 H), 2.31 (d, *J* = 6.0 Hz, 1 H), 1.36 (t, *J* = 7.2 Hz, 3 H), 1.25 ppm (d, *J* = 6.6 Hz, 3 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 187.5$, 163.9, 162.7, 148.9, 136.8, 128.5 (2 CH), 128.1 (3 CH), 121.2, 116.2, 85.8, 72.9 (CH₂), 68.8, 60.7 (CH₂), 18.9, 14.3, 14.2 ppm; IR (KBr): $\tilde{\nu}_{max} = 2980$, 2931, 1719, 1675, 1593, 1528, 1434, 1242, 1098, 746, 700 cm⁻¹; HRMS (ESI): *m*/z calcd for C₁₉H₂₂O₆Na [*M* + Na]⁺: 369.1314; found: 369.1319.

Ethyl 5-((25,35)-2-(benzyloxy)-3-hydroxybutanoyl)-2-phenylfuran-3-carboxylate **3g**. Prepared according to the general procedure discussed above: $R_{\rm f} = 0.30$; eluent, EtOAc/*n*-hexane (20%); isolated yield = 0.038 g, 64%; $[\alpha]_{\rm D}^{20} = -1$ (c = 0.10 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): δ = 8.06–8.09 (m, 2 H), 7.80 (s, 1 H), 7.45–7.49 (m, 3 H), 7.31–7.36 (m, 5 H), 4.78 (d, *J* = 11.4 Hz, 1 H), 4.52 (d, *J* = 11.4 Hz, 1 H), 4.45 (d, *J* = 5.1 Hz, 1 H), 4.33 (q, *J* = 7.2, 14.4 Hz, 2 H), 4.22–4.30 (m, 1 H), 2.20 (d, *J* = 6.9 Hz, 1 H), 1.35 (t, *J* = 7.2 Hz, 3 H), 1.28 ppm (d, *J* = 6.6 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): δ = 187.8, 162.4, 160.7, 148.9, 136.9, 130.8, 129.1 (2 CH), 128.5 (2 CH), 128.3 (3 CH), 128.2 (2 CH, C⁰), 122.7, 115.9, 85.9, 72.9 (CH₂), 68.8, 61.1 (CH₂), 190, 14.2 ppm; IR (KBr): $\tilde{\nu}_{max}$ = 2980, 2929, 1722, 1675, 1572, 1525, 1485, 1450, 1218, 1102, 762, 695 cm⁻¹; HRMS (ESI): *m/z* calcd for C₂₄H₂₄O₆Na [*M* + Na]⁺: 431.1471; found: 431.1484.

Methyl 5-((25,35)-2-(benzyloxy)-3-hydroxybutanoyl)-2-methoxyfuran-3-carboxylate **3h**. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (40%); isolated yield = 0.024 g, 48%; $[\alpha]_D^{20} = -14$ (c = 0.19 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 7.75$ (s, 1 H), 7.32–7.37 (m, 5 H), 4.73 (d, J = 12.0 Hz, 1 H), 4.47 (d, J = 11.4 Hz, 1 H), 4.26 (s, 3 H), 4.20 (d, J = 5.4 Hz, 1 H), 4.13–4.17 (m, 1 H), 3.82 (s, 3 H), 2.27 (d, J = 5.4 Hz, 1 H), 1.26 ppm (d, J = 6.0 Hz, 3 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 185.6$, 164.1, 162.1, 141.3, 136.8, 128.5 (2 CH), 128.2, 128.2 (2 CH), 125.0, 94.4, 85.9, 72.9 (CH₂), 69.0, 58.6, 51.6, 19.1 ppm; IR (KBr): $\tilde{v}_{max} = 2928$, 1718, 1659, 1598, 1545, 1409, 1244, 1100 cm⁻¹; HRMS (ESI): *m*/z calcd for C₁₈H₂₀O₇Na [*M* + Na]⁺: 371.1107; found: 371.1113.

Benzyl 5-((25,35)-2-(benzyloxy)-3-hydroxybutanoyl)-2-methylfuran-3-carboxylate **3i**. Prepared according to the general procedure discussed above: $R_f = 0.40$; eluent, EtOAc/*n*-hexane (25%); isolated yield =0.038 g, 64%; $[\alpha]_D^{20} = -2$ (c = 0.14 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 7.66$ (s, 1 H), 7.39–7.41 (m, 5 H), 7.31 (m, 5 H), 5.30 (s, 2 H), 4.72 (d, J = 11.4 Hz, 1 H), 4.45 (d, J = 11.4 Hz, 1 H), 4.33 (d, J = 5.1 Hz, 1 H), 4.16–4.22 (m, 1 H), 2.69 (s, 3 H), 2.12 (d, J = 6.9 Hz, 1 H), 1.24 ppm (d, J = 6.3 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 187.5$, 164.2, 162.5, 149.0, 136.8, 135.5, 128.6 (2 CH), 128.5 (2 CH), 128.4, 128.3 (2 CH), 128.1 (3 CH), 121.0, 115.9, 85.8, 72.9 (CH₂), 68.8, 66.5 (CH₂), 19.0, 14.4 ppm; IR (KBr): $\tilde{v}_{max} = 2927$, 1720, 1673, 1591, 1529, 1429, 1235, 1094, 745, 699 cm⁻¹; HRMS (ESI): m/z calcd for C₂₄H₂₄O₆Na [M + Na]⁺: 431.1471; found: 431.1487.

Ethyl 5-((2R,3R)-2,4-bis(benzyloxy)-3-hydroxybutanoyl)-2-methylfuran-3-carboxylate **3***j*. Prepared according to the general procedure discussed above: R_f = 0.30; eluent, EtOAc/*n*-hexane (22%); isolated yield =0.037 g, 74%; $[\alpha]_D^{20} = -1$ (c = 0.15 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 7.62$ (s, 1 H), 7.28–7.36 (m, 10 H), 4.68 (d, J = 11.7 Hz, 1 H), 4.54 (d, J = 11.7 Hz, 1 H), 4.49 (d, J = 5.1 Hz, 1 H), 4.43–4.46 (m, 2 H), 4.33 (q, J = 7.2, 14.4 Hz, 2 H), 4.16–4.24 (m, 1 H), 3.68 (d, J = 4.5 Hz, 2 H), 2.68 (s, 3 H), 2.56 (d, J = 7.2 Hz, 1 H), 1.37 ppm (t, J = 6.9 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 189.0$, 165.4, 164.3, 150.5, 139.1, 138.3, 130.0 (2 CH), 129.9 (2 CH), 129.7 (2 CH), 129.7, 129.3 (3 CH), 122.3, 117.6, 83.3, 74.9 (CH₂), 74.3 (CH₂), 73.1, 71.7 (CH₂), 62.2 (CH₂), 15.8 (2 CH₃) ppm; IR (KBr): $\tilde{\nu}_{max} = 2926$, 2864, 1720, 1676, 1592, 1530, 1453, 1236, 1093, 742, 699 cm⁻¹; HRMS (ESI): *m/z* calcd for C₂₆H₂₈O₇Na [*M* + Na]⁺: 475.1733; found: 475.1742.

Methyl 5-((2*R*,3*R*)-2,4-bis(benzyloxy)-3-hydroxybutanoyl)-2methylfuran-3-carboxylate **3k**. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (25%); isolated yield = 0.036 g, 75%; $[\alpha]_D^{20} = -1$ (c = 0.17 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 7.60$ (s, 1 H), 7.25– 7.34 (m, 10 H), 4.65 (d, J = 12.0 Hz, 1 H), 4.51 (d, J = 12.0 Hz, 1 H), 4.46 (d, J = 10.8 Hz, 1 H), 4.42–4.44 (m, 2 H), 4.15–4.19 (m, 1 H), 3.84 (s, 3 H), 3.66 (d, J = 4.2 Hz, 2 H), 2.66 (s, 3 H), 2.55–2.58 ppm (m, 1 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 187.4$, 163.9, 163.2, 149.0, 137.6, 136.7, 128.5 (2 CH), 128.4 (2 CH), 128.2 (2 CH), 128.1, 127.8, 127.8 (2 CH), 120.7, 115.8, 81.7, 73.4 (CH₂), 72.8 (CH₂), 71.6, 70.1 (CH₂), 51.7, 14.2 ppm; IR (KBr): $\tilde{\nu}_{max} = 2924$, 2865, 1722, 1677, 1594, 1530, 1449, 1244, 1100, 742, 699 cm⁻¹; HRMS (ESI): m/z calcd for C₂₅H₂₆O₇Na $[M + Na]^+$: 461.1577; found: 461.1577.

Isopropyl 5-((2R,3R)-2,4-bis(benzyloxy)-3-hydroxybutanoyl)-2methylfuran-3-carboxylate **31**. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (20%); isolated yield = 0.037 g, 71%; $[\alpha]_D^{20} = -1$ (c = 0.10 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 7.59$ (s, 1 H), 7.26– 7.33 (m, 10 H), 5.18 (dt, J = 6.3, 12.6 Hz, 1 H), 4.66 (d, J = 11.4 Hz, 1 H), 4.41–4.51 (m, 4 H), 4.15–4.22 (m, 1 H), 3.67 (d, J = 4.8 Hz, 2 H), 2.66 (s, 3 H), 2.53 (d, J = 7.2 Hz, 1 H), 1.33 ppm (d, J = 6.3 Hz, 6 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 187.4$, 163.7, 162.3, 148.9, 137.6, 136.8, 128.5 (2 CH), 128.4 (2 CH), 128.2 (2 CH), 128.1, 127.8 (3 CH), 120.9, 116.5, 81.7, 73.4 (CH₂), 72.8 (CH₂), 71.6, 70.1 (CH₂), 68.3, 21.9 (2 CH₃), 14.3 ppm; IR (KBr): $\tilde{\nu}_{max} = 2980$, 2928, 2867, 1714, 1676, 1593, 1529, 1245, 1097, 742, 700 cm⁻¹; HRMS (ESI): m/z calcd for C₂₇H₃₀O₇Na [M + Na]⁺: 489.1890; found: 489.1906.

Benzyl 5-((2R,3R)-2,4-bis(benzyloxy)-3-hydroxybutanoyl)-2methylfuran-3-carboxylate **3m**. Prepared according to the general procedure discussed above: $R_f = 0.40$; eluent, EtOAc/*n*-hexane (25%); isolated yield = 0.0485 g, 85%; $[\alpha]_D^{20} = -1$ (c = 0.12 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 7.62$ (s, 1 H), 7.41– 7.43 (m, 5 H), 7.26–7.32 (m, 10 H), 5.31 (s, 2 H), 4.66 (d, J = 11.4 Hz, 1 H), 4.53 (d, J = 12.0 Hz, 1 H), 4.48 (d, J = 5.4 Hz, 1 H), 4.43 (d, J =11.4 Hz, 2 H), 4.15–4.22 (m, 1 H), 3.67 (d, J = 4.2 Hz, 2 H), 2.68 (s, 3 H), 2.53 ppm (d, J = 7.2 Hz, 1 H); ¹³C NMR (75 MHz, CDCl₃): $\delta =$ 187.4, 164.1, 162.6, 149.0, 137.6, 136.8, 135.6, 128.6 (2 CH), 128.4 (2 CH), 128.4 (3 CH), 128.3 (2 CH), 128.2 (3 CH), 128.1, 127.8 (2 CH), 120.6, 115.8, 81.7, 73.4 (CH₂), 72.8 (CH₂), 71.5, 70.1 (CH₂), 66.4 (CH₂), 14.3 ppm; IR (KBr): $\tilde{\nu}_{max} = 2925$, 2864, 1720, 1676, 1592, 1530, 1236, 1094, 743, 699 cm⁻¹; HRMS (ESI): *m*/*z* calcd for C₃₁H₃₀O₇Na [*M* + Na]⁺: 537.1890; found: 537.1899.

Ethyl 5-((2R,3R)-2,4-bis(benzyloxy)-3-hydroxybutanoyl)-2-phenylfuran-3-carboxylate 3n. Prepared according to the general procedure discussed above: $R_f = 0.31$; eluent, EtOAc/*n*-hexane (20%); isolated yield = 0.032 g, 56%; $[\alpha]_D^{20} = -1$ (c = 0.10 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): δ = 8.08 (dd, J = 1.8, 6.9 Hz, 2 H), 7.76 (s, 1 H), 7.47–7.49 (m, 3 H), 7.28–7.33 (m, 10 H), 4.72 (d, J = 11.4 Hz, 1 H), 4.59 (d, J = 6.9 Hz, 1 H), 4.51 (t, J = 7.2 Hz, 3 H), 4.34 (q, J = 7.5, 14.4 Hz, 2 H), 4.22–4.29 (m, 1 H), 3.71 (d, J = 4.5 Hz, 2 H), 2.59 (d, J = 7.2 Hz, 1 H), 1.36 ppm (t, J = 6.9 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): δ = 187.6, 162.4, 160.5, 149.0, 137.6, 136.8, 130.8, 129.1 (2 CH), 128.5 (2 CH), 128.4 (3 CH), 128.2 (4 CH), 128.2, 127.8 (3 CH), 122.2, 115.9, 81.7, 73.4 (CH₂), 72.8 (CH₂), 71.6, 70.1 (CH₂), 61.0 (CH₂), 14.2 ppm; IR (KBr): \tilde{v}_{max} = 2926, 2865, 1722, 1677, 1576, 1526, 1485, 1217, 1102, 761, 696 cm⁻¹; HRMS (ESI): m/z calcd for $C_{31}H_{30}O_7Na [M + Na]^+$: 537.1890; found: 537,1904.

Ethyl 5-((2R,3R)-2,4-bis(benzyloxy)-3-hydroxybutanoyl)-2-(ptolyl)furan-3-carboxylate 30. Prepared according to the general procedure discussed above: $R_{\rm f} = 0.30$; eluent, EtOAc/n-hexane (20%); isolated yield = 0.0355 g, 61%; $[\alpha]_{\rm D}^{20} = -1$ (c = 0.10 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): δ = 7.98 (d, J = 8.4 Hz, 2 H), 7.74 (s, 1 H), 7.30-7.34 (m, 5 H), 7.28-7.30 (m, 5 H), 7.25-7.26 (m, 2 H), 4.70 (d, J = 11.4 Hz, 1 H), 4.58 (d, J = 6.6 Hz, 1 H), 4.53 (d, J = 12.0 Hz, 1 H), 4.48 (dd, J = 3.0, 12.0 Hz, 2 H), 4.31 (q, J = 12.0 Hz, 2 Hz), 4.31 (q, J = 12.0 Hz), 4.31 (q, J = 12.0*J* = 7.2, 14.4 Hz, 2 H), 4.24 (quin, *J* = 4.2 Hz, 1 H), 3.68 (d, *J* = 4.2 Hz, 2 H), 2.65 (d, J = 7.2 Hz, 1 H), 2.42 (s, 3 H), 1.34 ppm (t, J = 6.6 Hz, 3 H); ^{13}C NMR (150 MHz, CDCl₃): δ = 188.6, 163.5, 161.9, 149.8, 142.3, 138.6, 137.9, 130.1 (2 CH), 130.0 (2 CH), 129.5 (2 CH), 129.4 (2 CH), 129.3 (2 CH), 129.2 (2 CH), 128.8 (2 CH), 126.6, 123.4, 116.4, 82.7, 74.4 (CH₂), 73.8 (CH₂), 72.6, 71.2 (CH₂), 62.0 (CH₂), 22.6, 15.2 ppm; IR (KBr): $\tilde{\nu}_{max}$ = 2925, 2863, 1722, 1676, 1583, 1493, 1215, 1100, 1027, 742, 698 cm⁻¹; HRMS (ESI): m/z calcd for $C_{32}H_{32}O_7Na [M + Na]^+$: 551.2046; found: 551.2044.

Ethyl 5-((2R,3R)-2, 4-bis(benzyloxy)-3-hydroxybutanoyl)-2-(m-tolyl)furan-3-carboxylate **3p**. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (20%); isolated yield = 0.035 g, 60%; $[\alpha]_D^{20} = +1$ (c = 0.12 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 7.86-7.89$ (m, 2 H), 7.76 (s, 1 H), 7.28-7.36 (m, 12 H), 4.72 (d, J = 11.7 Hz, 1 H), 4.58 (d, J = 6.9 Hz, 1 H), 4.51 (t, J = 7.8 Hz, 3 H), 4.33 (q, J = 6.9, 14.4 Hz, 2 H), 4.22-4.28 (m, 1 H), 3.71 (d, J = 4.2 Hz, 2 H), 2.60 (d, J =7.2 Hz, 1 H), 2.43 (s, 3 H), 1.36 ppm (t, J = 7.5 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 187.6$, 162.4, 160.8, 148.9, 137.9, 137.6, 136.8, 131.6, 129.5, 128.5 (2 CH), 128.4 (2 CH), 128.2 (2 CH), 128.1, 128.1, 127.8, 127.8 (2 CH), 126.4 (CH, C), 122.3, 115.8, 81.7, 73.4 (CH₂), 72.8 (CH₂), 71.6, 70.1 (CH₂), 61.0 (CH₂), 21.4, 14.2 ppm; IR (KBr): $\bar{\nu}_{max}$ = 2925, 2863, 1721, 1678, 1574, 1522, 1455, 1222, 1100, 742, 699 cm⁻¹; HRMS (ESI): *m/z* calcd for C₃₂H₃₂O₇Na [*M* + Na]⁺: 551.2046; found: 551.2040.

Ethyl 5-((2R,3R)-2,4-bis(benzyloxy)-3-hydroxybutanoyl)-2-(4chlorophenyl)furan-3-carboxylate 3q. Prepared according to the general procedure discussed above: $R_f = 0.40$; eluent, EtOAc/*n*-hexane (25%); isolated yield = 0.037 g, 61%; $[\alpha]_D^{20} = -1$ (c = 0.30 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): δ = 8.07 (d, J = 8.7 Hz, 2 H), 7.76 (s, 1 H), 7.44 (d, J = 8.7 Hz, 2 H), 7.28-7.33 (m, 10 H), 4.71 (d, J = 11.7 Hz, 1 H), 4.56 (d, J = 6.6 Hz, 1 H), 4.51 (t, J = 7.2 Hz, 3 H), 4.34 (q, J = 7.2, 14.4 Hz, 2 H), 4.21–4.29 (m, 1 H), 3.71 (d, J = 4.2 Hz, 2 H), 2.59 (d, J = 7.2 Hz, 1 H), 1.37 ppm (t, J = 7.2 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): δ = 189.2, 163.8, 160.7, 150.6, 139.1, 138.5, 138.3, 131.9 (2 CH), 130.1 (2 CH), 130.0 (2 CH), 129.9 (2 CH), 129.8 (2 CH), 129.7, 129.4, 129.3 (2 CH), 128.3, 123.7, 117.7, 83.3, 75.0 (CH₂), 74.4 (CH₂), 73.2, 71.7 (CH₂), 62.7 (CH₂), 15.7 ppm; IR (KBr): $\tilde{\nu}_{max} = 2926, 2861, 1722, 1676, 1585, 1480, 1268,$ 1217, 1096, 1023, 838, 740, 699 cm⁻¹; HRMS (ESI): m/z calcd for $C_{31}H_{29}ClO_7Na [M + Na]^+: 571.1500; found: 571.1498.$

Methyl 5-((2R,3R)-2,4-bis(benzyloxy)-3-hydroxybutanoyl)-2-methoxyfuran-3-carboxylate **3r**. Prepared according to the general procedure discussed above: $R_f = 0.40$; eluent, EtOAc/*n*-hexane (42%); isolated yield = 0.025 g, 50%; $[\alpha]_D^{20} = -1$ (c = 0.16 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 7.69$ (s, 1 H), 7.25–7.35 (m, 10 H), 4.65 (d, J = 11.4 Hz, 1 H), 4.52 (d, J = 12.0 Hz, 1 H), 4.48 (d, J = 11.4 Hz, 1 H), 4.43 (d, J = 11.4 Hz, 1 H), 4.35 (d, J = 7.2 Hz, 1 H), 4.22 (s, 3 H), 4.12–4.16 (m, 1 H), 3.82 (s, 3 H), 3.67 (d, J = 4.2 Hz, 2 H), 2.59 ppm (d, J = 7.2 Hz, 1 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 185.5$, 164.1, 162.2, 141.3, 137.6, 136.8, 128.5 (2 CH), 128.4 (2 CH), 128.2 (2 CH), 128.2, 127.8, 127.8 (2 CH), 124.5, 94.3, 81.4, 73.4 (CH₂), 72.7 (CH₂), 71.7, 70.2 (CH₂), 58.5, 51.6 ppm; IR (KBr): $\tilde{\nu}_{max} = 2925$, 2866, 1719, 1663, 1598, 1545, 1409, 1245, 1099, 743, 701 cm⁻¹; HRMS (ESI): m/z calcd for C₂₅H₂₆O₈Na [M + Na]⁺: 477.1526; found: 477.1540.

Benzyl 5-((2R,3R)-4-((tert-butyldiphenylsilyl)oxy)-2,3-dihydroxybutanoyl)-2-methylfuran-3-carboxylate 3s. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/ *n*-hexane (30%); isolated yield = 0.025 g, 44%; $[\alpha]_{\rm D}^{20} = -1$ (c = 0.14 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 7.57-$ 7.60 (m, 5 H), 7.39–7.43 (m, 6 H), 7.34–7.38 (m, 5 H), 5.34 (d, J = 12.0 Hz, 1 H), 5.30 (d, J = 12.0 Hz, 1 H), 4.89 (t, J = 6.6 Hz, 1 H), 3.98-4.02 (m, 1 H), 3.74-3.79 (m, 2 H), 3.61 (d, J = 7.8 Hz, 1 H), 2.73 (d, J = 8.4 Hz, 1 H), 2.67 (s, 3 H), 1.00 ppm (s, 9 H); ¹³C NMR (150 MHz, CDCl₃): δ = 187.5, 164.2, 162.4, 148.5, 135.5, 135.5 (2 CH), 135.4 (2 CH), 132.5 (2 C⁰), 129.9, 129.9, 128.7 (2 CH), 128.5, 128.3 (2 CH), 127.8 (2 CH), 127.8 (2 CH), 120.5, 116.1, 74.4, 73.4, 66.6 (CH₂), 63.7 (CH₂), 26.7 (3 CH₃), 19.1, 14.4 ppm; IR (KBr): $\tilde{v}_{max} = 2928, 2857, 1721, 1674, 1594, 1533, 1427, 1236,$ 1109, 743, 702 cm⁻¹; HRMS (ESI): m/z calcd for C₃₃H₃₆O₇SiNa $[M + Na]^+$: 595.2128; found: 595.2106.

2-((2R,3R)-2,4-Bis(benzyloxy)-3-hydroxybutanoyl)-6,6-dimethyl-6.7-dihydrobenzofuran-4(5H)-one 3t and 3-((2R,3R)-2,4-Bis-(benzyloxy)-3-hydroxybutanoyl)-6,6-dimethyl-6,7-dihydrobenzofuran-4(5H)-one 4t. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/n-hexane (28%); isolated yield = 0.021 g, 41%; colorless gum; 3t:4t = 86:14; inseparable mixtures. Major peaks: ¹H NMR (600 MHz, CDCl₃): δ = 7.60 (s, 1 H), 7.24–7.35 (m, 10 H), 4.65 (d, J = 12.0 Hz, 1 H), 4.51 (d, J = 12.0 Hz, 1 H), 4.46 (d, J = 12.0 Hz, 1 H), 4.42–4.44 (m, 2 H), 4.16 (m, 1 H), 3.67 (dd, J = 1.2, 4.8 Hz, 2 H), 2.81 (s, 2 H), 2.54 (d, J = 7.2 Hz, 1 H), 2.42 (s, 2 H), 1.16 (s, 3 H), 1.15 ppm (s, 3 H); ¹³C NMR (150 MHz, $CDCl_3$): $\delta = 193.3$, 188.1, 169.8, 151.2, 137.6, 136.7, 128.5 (2 CH), 128.4 (2 CH), 128.2 (3 CH), 127.8, 127.8 (2 CH), 121.4, 115.8, 81.9, 73.4 (CH₂), 72.9 (CH₂), 71.6, 70.0 (CH₂), 52.0 (CH₂), 37.5 (CH₂), 35.1, 28.6, 28.5 ppm; IR (KBr): $\tilde{\nu}_{\rm max}$ = 2958, 2928, 2869, 1677, 1584, 1525, 1452, 1208, 1118, 742, 699 cm⁻¹; HRMS (ESI): *m/z* calcd for $C_{28}H_{30}O_6Na [M + Na]^+$: 485.1940; found: 485.1922.

(2R,3R)-1-(4-Benzoyl-5-phenylfuran-2-yl)-2,4-bis(benzyloxy)-3hydroxybutan-1-one 3u and (2Ŕ,3R)-1-(4-Benzoyl-5-phenylfurán-3yl)-2,4-bis(benzyloxy)-3-hydroxybutan-1-one 4u. Prepared according to the general procedure discussed above: $R_f = 0.40$; eluent, EtOAc/ *n*-hexane (25%); isolated yield = 0.010 g, 16%; $[\alpha]_D^{20} = -1$ (c = 0.40 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): δ = 7.79 (t, J = 7.2 Hz, 3 H), 7.53–7.56 (m, 2 H), 7.26–7.42 (m, 16 H), 4.71 (d, J = 11.4 Hz, 1 H), 4.59 (d, J = 6.9 Hz, 1 H), 4.46–4.52 (m, 3 H), 4.21-4.28 (m, 1 H), 3.70 (d, J = 3.9 Hz, 2 H), 2.60 ppm (d, J = 7.2 Hz, 1 H); ¹³C NMR (75 MHz, CDCl₃): δ = 190.5, 187.7, 158.8, 149.2, 137.6, 137.2, 136.8, 133.4, 130.5, 129.7 (2 CH), 128.6 (2 CH), 128.5 (2 CH), 128.5 (2 CH), 128.4 (2 CH), 128.3, 128.2 (2 CH), 128.2 (3 CH), 127.8, 127.7 (2 CH), 122.5, 122.2, 81.7, 73.4 (CH₂), 72.9 (CH₂), 71.6, 70.1 (CH₂) ppm; IR (KBr): $\tilde{\nu}_{max}$ = 2924, 2858, 1660, 1565, 1480, 1450, 1389, 1265, 1075, 893, 732, 695 cm⁻¹; HRMS (ESI): m/z calcd for $C_{35}H_{30}O_6Na [M + Na]^+$: 569.1940; found: 569.1942.

Ethyl 5-((2S,3R)-2,4-bis(benzyloxy)-3-hydroxybutanoyl)-2-phenylfuran-3-carboxylate 3v and Ethyl 4-((2S,3R)-2,4-bis(benzyloxy)-3hydroxybutanoyl)-2-phenylfuran-3-carboxylate 4v. Prepared according to the general procedure discussed above: $R_{\rm f}$ = 0.30; eluent, EtOAc/n-hexane (20%); isolated yield = 0.034 g, 60%; colorless gum; 3v:4v = 86:14; inseparable mixtures. Major peaks: ¹H NMR $(300 \text{ MHz}, \text{CDCl}_3): \delta = 8.05 - 8.08 \text{ (m, 2 H)}, 7.76 \text{ (s, 1 H)}, 7.43 - 7.47$ (m, 3 H), 7.24–7.32 (m, 10 H), 4.78 (d, J = 11.4 Hz, 1 H), 4.69 (d, J = 4.2 Hz, 1 H), 4.42-4.51 (m, 3 H), 4.32 (q, I = 6.9, 14.1 Hz, 2 H), 4.20-4.28 (m, 1 H), 3.60 (d, J = 5.4 Hz, 2 H), 2.63 (d, J = 6.6 Hz, 1 H), 1.34 ppm (t, J = 7.2 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): $\delta =$ 187.2, 162.4, 160.5, 148.8, 137.6, 136.7, 130.8, 129.1 (2 CH), 128.5 (2 CH), 128.4 (2 CH), 128.3 (2 CH), 128.3 (3 CH), 127.7 (3 CH, C⁰), 122.4, 115.9, 81.8, 73.4 (CH₂), 73.0 (CH₂), 71.6, 70.1 (CH₂), 61.1 (CH₂), 14.2 ppm; IR (KBr): $\tilde{\nu}_{max} = 2927$, 2867, 1722, 1675, 1575, 1526, 1486, 1451, 1390, 1218, 1102, 760, 696 cm⁻¹; HRMS (ESI): m/z calcd for C₃₁H₃₀O₇Na $[M + Na]^+$: 537.1890; found: 537.1890.

Ethyl 5-((25,3*R*)-2,4-bis(bdenzyloxy)-3-hydroxybutanoyl)-2-(*p*-tolyl)furan-3-carboxylate **3w**. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (20%); isolated yield = 0.0325 g, 56%; $[\alpha]_D^{20} = +1$ (c = 0.10 in MeOH); colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 8.00$ (d, J = 8.4 Hz, 2 H), 7.77 (s, 1 H), 7.23–7.34 (m, 12 H), 4.79 (d, J = 11.4 Hz, 1 H), 4.71 (d, J = 4.2 Hz, 1 H), 4.43–4.52 (m, 3 H), 4.33 (q, J = 7.2, 14.4 Hz, 2 H), 4.22–4.27 (m, 1 H), 3.62 (d, J = 6.0 Hz, 2 H), 2.66 (d, J = 6.6 Hz, 1 H), 2.43 (s, 3 H), 1.36 ppm (t, J = 7.2 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 187.1$, 162.5, 160.9, 148.5, 141.3, 137.6, 136.8, 129.0 (5 CH), 128.5 (2 CH), 128.4 (2 CH), 128.3 (2 CH), 128.2, 127.7 (2 CH), 125.5, 122.6, 115.4, 81.7, 73.4 (CH₂), 73.0 (CH₂), 71.6, 70.1 (CH₂), 61.0 (CH₂), 21.6, 14.2 ppm; IR (KBr): $\tilde{v}_{max} = 2926$, 1721, 1666, 1585, 1493, 1269, 1216, 1099, 742, 699 cm⁻¹; HRMS (ESI): m/z calcd for C₃₂H₃₂O₇Na [M + Na]⁺: S51.2046; found: S51.2056.

Ethyl 5-((2S,3R)-2,4-bis(benzyloxy)-3-hydroxybutanoyl)-2-(4chlorophenyl)furan-3-carboxylate **3x** and Ethyl 4-((2S,3R)-2,4-bis(benzyloxy)-3-hydroxybutanoyl)-2-(4-chlorophenyl)furan-3-carboxylate 4x. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/n-hexane (20%); isolated yield = 0.026 g, 43%; colorless gum; 3x:4x = 88:12; inseparable mixtures. Major peaks: ¹H NMR (600 MHz, CDCl₃): δ = 8.05 (d, J = 8.4 Hz, 2 H), 7.76 (s, 1 H), 7.38 (d, J = 8.4 Hz, 2 H), 7.22-7.34 (m, 10 H), 4.78 (d, J = 11.4 Hz, 1 H), 4.68 (d, J = 4.2 Hz, 1 H), 4.43-4.51 (m, 3 H), 4.32 (q, J = 7.2, 14.4 Hz, 2 H), 4.24 (br. s., 1 H), 3.61 (d, J = 6.0 Hz, 2 H), 2.69 (br. s., 1 H), 1.35 ppm (t, J = 7.8 Hz, 3 H); ¹³C NMR (150 MHz, CDCl₃): δ = 187.3, 162.3, 159.2, 148.8, 137.6, 137.0, 136.7, 130.3 (2 CH), 128.6 (2 CH), 128.5 (2 CH), 128.4 (2 CH), 128.4 (2 CH), 128.3, 127.8, 127.7 (2 CH), 126.7, 122.4, 116.2, 81.9, 73.4 (CH₂), 73.1 (CH₂), 71.6, 70.1 (CH₂), 61.2 (CH₂), 14.2 ppm; IR (KBr): \tilde{v}_{max} = 2924, 2854, 1723, 1682, 1586, 1478, 1268, 1218, 1095, 839, 741, 700 cm⁻¹; HRMS (ESI): m/z calcd for $C_{31}H_{29}ClO_7Na$ $[M + Na]^+$: 571.1500; found: 571.1518.

Methyl 5-((2S,3R)-2,4-bis(benzyloxy)-3-hydroxybutanoyl)-2-methoxyfuran-3-carboxylate **3y**. Prepared according to the general procedure discussed above: $R_f = 0.40$; eluent, EtOAc/*n*-hexane (40%); isolated yield = 0.02 g, 40%; $[\alpha]_D^{20} = -1$ (c = 0.10 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): δ = 7.69 (s, 1 H), 7.27–7.35 (m, 8 H), 7.23–7.25 (m, 2 H), 4.73 (d, *J* = 12.0 Hz, 1 H), 4.47 (d, *J* = 4.2 Hz, 1 H), 4.42–4.45 (m, 3 H), 4.18 (s, 3 H), 4.12 (quin, *J* = 6.0 Hz, 1 H), 3.81 (s, 3 H), 3.56 (dd, *J* = 3.0, 5.4 Hz, 2 H), 2.66 ppm (d, *J* = 6.6 Hz, 1 H); ¹³C NMR (150 MHz, CDCl₃): δ = 185.1, 164.1, 162.1, 141.1, 137.6, 136.7, 128.5 (2 CH), 128.4 (2 CH), 128.3 (2 CH), 128.3, 127.7 (2 CH), 127.7, 124.6, 94.4, 81.5, 73.4 (CH₂), 72.9 (CH₂), 71.8, 70.1 (CH₂), 58.5, 51.6 ppm; IR (KBr): $\tilde{\nu}_{max}$ = 2925, 2861, 1719, 1655, 1598, 1545, 1408, 1243, 1100, 744, 700 cm⁻¹; HRMS (ESI): *m*/*z* calcd for C₂₅H₂₆O₈Na [*M* + Na]⁺: 477.1526; found: 477.1508.

Benzyl (R)-5-(2-(benzyloxy)-3-hydroxypropanoyl)-2-methylfuran-3-carboxylate **3z**. Prepared according to the general procedure discussed above: $R_f = 0.40$; eluent, EtOAc/*n*-hexane (25%); isolated yield = 0.045 g, 76%; $[\alpha]_D^{20} = -1$ (c = 0.10 in MeOH); colorless gum. ¹H NMR (600 MHz, CDCl₃): $\delta = 7.67$ (s, 1 H), 7.36–7.43 (m, 5 H), 7.31–7.34 (m, 5 H), 5.32 (d, J = 12.0 Hz, 1 H), 5.29 (d, J = 12.6 Hz, 1 H), 4.75 (d, J = 11.4 Hz, 1 H), 4.55 (dd, J = 3.6, 6.0 Hz, 1 H), 4.52 (d, J = 11.4 Hz, 1 H), 3.95 (ddd, J = 4.2, 7.8, 12.0 Hz, 1 H), 3.90 (dt, J = 6.0, 12.0 Hz, 1 H), 2.69 (s, 3 H), 2.22 ppm (t, J = 6.6 Hz, 1 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 186.7$, 164.3, 162.5, 148.5, 136.7, 135.5, 128.7 (2 CH), 128.6 (2 CH), 128.4, 128.3 (3 CH), 128.2 (2 CH), 121.0, 115.9, 82.8, 72.8 (CH₂), 66.5 (CH₂), 63.6 (CH₂), 14.4 ppm; IR (KBr): $\tilde{v}_{max} = 2927$, 1720, 1675, 1592, 1530, 1429, 1236, 1096, 744, 699 cm⁻¹; HRMS (ESI): *m*/z calcd for C₂₃H₂₂O₆Na [*M* + Na]⁺: 417.1314; found: 417.1304.

Benzyl 5-(2-(benzyloxy)acryloyl)-2-methylfuran-3-carboxylate 5a. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (10%); isolated yield = 0.041 g, 87%; white solid, mp 122–124 °C; solvent of crystallization, acetone. ¹H NMR (600 MHz, CDCl₃): $\delta = 7.70$ (s, 1 H), 7.38–7.44 (m, 7 H), 7.33–7.34 (m, 3 H), 5.47 (d, J = 3.0 Hz, 1 H), 5.28 (s, 2 H), 4.98 (s, 2 H), 4.74 (d, J = 3.0 Hz, 1 H), 2.71 ppm (s, 3 H); ¹³C NMR (150 MHz, CDCl₃): $\delta = 175.5$, 164.6, 162.8, 157.3, 148.4, 135.7, 135.6, 128.7 (2 CH), 128.7 (2 CH), 128.4, 128.4, 128.3 (2 CH), 127.7 (2 CH), 122.9, 115.7, 94.1 (CH₂), 70.7 (CH₂), 66.4 (CH₂), 14.4 ppm; IR (KBr): $\tilde{\nu}_{max} = 3140$, 2951, 1707, 1656, 1605, 1411, 1329, 1278, 1227, 1136, 1086, 1020, 954, 867, 753, 699 cm⁻¹; HRMS (ESI): *m/z* calcd for C₂₃H₂₀O₅Na [*M* + Na]⁺: 399.1209; found: 399.1219.

Benzyl (E)-5-(2-(benzyloxy)but-2-enoyl)-2-methylfuran-3-carboxylate **5b**. Prepared according to the general procedure discussed above: $R_f = 0.30$; eluent, EtOAc/*n*-hexane (10%); isolated yield = 0.03 g, 63%; colorless gum. ¹H NMR (300 MHz, CDCl₃): $\delta = 7.50$ (s, 1 H), 7.31–7.43 (m, 10 H), 6.28 (q, J = 7.2 Hz, 1 H), 5.31 (s, 2 H), 4.84 (s, 2 H), 2.71 (s, 3 H), 1.80 ppm (d, J = 6.9 Hz, 3 H); ¹³C NMR (75 MHz, CDCl₃): $\delta = 177.6$, 164.2, 162.7, 152.2, 149.0, 136.5, 135.7, 128.6 (2 CH), 128.6 (2 CH), 128.5 (2 CH), 128.4, 128.3, 128.3 (2 CH), 125.0, 121.1, 115.5, 73.7 (CH₂), 66.4 (CH₂), 14.4, 11.5 ppm; IR (KBr): $\tilde{\nu}_{max} = 3033$, 2927, 1721, 1644, 1528, 1430, 1308, 1238, 1135, 1077, 876, 757, 697 cm⁻¹; HRMS (ESI): *m*/*z* calcd for C₂₄H₂₂O₅Na [*M* + Na]⁺: 413.1365; found: 413.1357.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.5b02500.

Copies of 1D and 2D NMR spectra (PDF) X-ray crystal structure of **5a** (CIF)

AUTHOR INFORMATION

Corresponding Author

*E-mail: id@csiriicb.in.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

I.D. thanks DST-SERB, India (Grant No. SB/FT/CS-105/2012) for financial support and Drs. Ramalingam Natarajan and Basudeb Achari for valuable discussions. K.M. thanks CSIR-India for his fellowship. The authors thank Mr. Fazle Haque for carrying out some preliminary works in this project.

REFERENCES

 For recent reviews, see: (a) Dorel, R.; Echavarren, A. M. Chem. Rev. 2015, 115, 9028–9072. (b) Gulevich, A. V.; Dudnik, A. S.; Chernyak, N.; Gevorgyan, V. Chem. Rev. 2013, 113, 3084–3213.
 (c) Boto, A.; Alvarez, L. Heterocycles in Natural Product Synthesis; Majumdar, K. C., Chattopadhyay, S. K., Eds.; Wiley-VCH: Weinheim, Germany, 2011; pp 97–152. (d) Wong, H. N. C.; Yeung, K.-S.; Yang, Z. Comprehensive Heterocyclic Chemistry; Katritzky, A. R., Ramsden, C. A., Scriven, E. F. V., Taylor, R. J. K., Eds.; Elsevier: Oxford, 2008; Vol. 3, pp 408–496. (e) Brown, R. C. D. Angew. Chem., Int. Ed. 2005, 44, 850–852. (f) Gammill, R. B. J. Org. Chem. 1979, 44, 3988–3990.
 (g) Paquette, L. A.; Astles, P. C. J. Org. Chem. 1993, 58, 165–169.
 (h) Tius, M. A. Chem. Rev. 1988, 88, 719–732.

(2) For selected reviews, see: (a) Harris, J. M.; Li, M.; Scott, J. G.; O'Doherty, G. A. Achmatowicz Approach To 5,6-Dihydro-2H-Pyran-2-One Containing Natural Products in Strategy and Tactics in Natural Product Synthesis; Harmata, M., Ed.; Elsevier: London, 2004. (b) Achmatowicz, O.; Bielski, R. Carbohydr. Res. 1977, 55, 165-176. (3) For selected references, see: (a) Heravi, M. M.; Daraie, M.; Zadsirjan, V. Mol. Diversity 2015, 19, 577-623. (b) Zhang, L.; Peng, X.-M.; Damu, G. L. V.; Geng, R.-X.; Zhou, C.-H. Med. Res. Rev. 2014, 34, 340-437. (c) Sheng, J.; Chao, B.; Chen, H.; Hu, Y. Org. Lett. 2013, 15, 4508-4511. (d) Chao, B.; Lin, S.; Ma, Q.; Lu, D.; Hu, Y. Org. Lett. 2012, 14, 2398-2401. (e) Díez-González, S.; Marion, N.; Nolan, S. P. Chem. Rev. 2009, 109, 3612-3676. (f) Plaquevent, J.-C.; Levillain, J.; Guillen, F.; Malhiac, C.; Gaumont, A.-C. Chem. Rev. 2008, 108, 5035-5060. (g) Bellina, F.; Cauteruccio, S.; Rossi, R. Tetrahedron 2007, 63, 4571-4624. (h) Terasawa, K.; Sugita, Y.; Yokoe, I.; Fujisawa, S.; Sakagami, H. Anticancer Res. 2001, 21, 1081-1086.

(4) For selected references, see: (a) Butkevich, A. N.; Meerpoel, L.; Stansfield, I.; Angibaud, P.; Corbu, A.; Cossy, J. Org. Lett. **2013**, 15, 3840–3843. (b) Cordonniera, R.; Nguyen Van Nhiena, A.; Sorianob, E.; Marco-Contellesb, J.; Postel, D. Tetrahedron **2010**, 66, 736–742. (c) Majer, J.; Kwiatkowski, P.; Jurczak, J. Org. Lett. **2008**, 10, 2955– 2958. (d) Boto, A.; Hernández, D.; Hernández, R. Org. Lett. **2007**, 9, 1721–1724. (e) Kobayashi, Y.; Kusakabe, M.; Kitano, Y.; Sato, F. J. Org. Chem. **1988**, 53, 1586–1587. (f) Garcia Gonzalez, F. Adv. Carbohydr. Chem. **1956**, 11, 97–143.

(5) For selected references, see: (a) Brust, A.; Cuny, E. Green Chem. 2013, 15, 2993–2998. (b) Albrecht, Ł.; Ransborg, L. K.; Jørgensen, K. A. Catal. Sci. Technol. 2012, 2, 1089–1098. (c) Albrecht, Ł.; Ransborg, L. K.; Albrecht, A.; Lykke, L.; Jørgensen, K. A. Chem. - Eur. J. 2011, 17, 13240–13246. (d) Bagdanoff, J. T.; Donoviel, M. S.; Nouraldeen, A.; Carlsen, M.; Jessop, T. C.; Tarver, J.; Aleem, S.; Dong, L.; Zhang, H.; Boteju, L.; Hazelwood, J.; Yan, J.; Bednarz, M.; Layek, S.; Owusu, I. B.; Gopinathan, S.; Moran, L.; Lai, Z.; Kramer, J.; Kimball, S. D.; Yalamanchili, P.; Heydorn, W. E.; Frazier, K. S.; Brooks, B.; Brown, P.; Wilson, A.; Sonnenburg, W. K.; Main, A.; Carson, K. G.; Oravecz, T.; Augeri, D. J. J. Med. Chem. 2010, 53, 8650–8662. (e) Harusawa, S.; Murai, Y.; Moriyama, H.; Imazu, T.; Ohishi, H.; Yoneda, R.; Kurihara, T. J. Org. Chem. 1996, 61, 4405–4411. (f) Harusawa, S.; Murai, Y.; Moriyama, H.; Ohishi, H.; Yoneda, R.; Kurihara, T. Tetrahedron Lett. 1995, 36, 3165–3168.

(6) (a) Hollingsworth, R. I.; Wang, G. Chem. Rev. 2000, 100, 4267–4282. (b) Hanessian, S. Total Synthesis of Natural Products: The Chiron Approach; Pergamon Press: Oxford, 1983. (c) Ferrier, R. J. Carbohydrate Chemistry: Monosaccharides, Disaccharides and Specific Oligosaccharides; The Royal Society of Chemistry: Cambridge, 1968–2001; Vols. 1–32.

(7) For selected references, see: (a) Peh, G. R.; Floreancig, P. E. Org. Lett. 2015, 17, 3750-3753. (b) Xiong, D.-C.; Zhang, L.-H.; Ye, X.-S.

Org. Lett. **2009**, *11*, 1709–1712. (c) Leonelli, F.; Capuzzi, M.; Calcagno, V.; Passacantilli, P.; Piancatelli, G. *Eur. J. Org. Chem.* **2005**, 2005, 2671–2676. (d) Gardiner, J. M.; Mills, R.; Fessard, T. *Tetrahedron Lett.* **2004**, *45*, 1215–1217. (e) Chemler, S. R.; Iserloh, U.; Danishefsky, S. J. *Org. Lett.* **2001**, *3*, 2949–2951. (f) Ramnauth, J.; Poulin, O.; Bratovanov, S. S.; Rakhit, S.; Maddaford, S. P. *Org. Lett.* **2001**, *3*, 2571–2573. (g) McDonald, L. A.; Foster, M. P.; Phillips, D. R.; Ireland, C. M.; Lee, A. Y.; Clardy, J. J. Org. Chem. **1992**, 57, 4616–4624. (h) Tsogoeva, S. B. *Eur. J. Org. Chem.* **2007**, 2007, 1701–1716. (8) (a) Mal, K.; Kaur, A.; Das, I. *Asian J. Org. Chem.* **2015**, *4*, 1132–1143. (b) Mal, K.; Sharma, A.; Das, I. Chem. - Eur. J. **2014**, 20, 11932–11945.

(9) For the synthesis of carbohydrate-based 2-haloenones, see ref. (7c) and (8); see also Kirschning, A. J. Org. Chem. **1995**, 60, 1228–1232.

(10) (a) Nikitina, P. A.; Peregudov, A. S.; Koldaeva, T. Y.; Kuz'mina, L. G.; Adiulin, E. I.; Tkach, I. I.; Perevalov, V. P. *Tetrahedron* **2015**, *71*, 5217–5228. (b) Minkin, V. I.; Garnovskii, A. D.; Elguero, J.; Katritzky, A. R.; Denisko, O. V. Adv. Heterocycl. Chem. **2000**, *76*, 157–323.

(11) (a) Jacobsen, N. E. Two-Dimensional NMR Spectroscopy: HETCOR, COSY, and TOCSY, in NMR Spectroscopy Explained: Simplified Theory, Applications and Examples for Organic Chemistry and Structural Biology; John Wiley & Sons, Inc.: Hoboken, NJ, 2007.
(b) Claridge, T. D. W. High-Resolution NMR Techniques in Organic Chemistry; Pergamon: Oxford, 1999.

(12) Dharuman, S.; Vankar, Y. D. Org. Lett. 2014, 16, 1172-1175.

(13) Shao, H.; Ekthawatchai, S.; Chen, C.-S.; Wu, S.-H.; Zou, W. J. Org. Chem. 2005, 70, 4726–4734.

(14) CCDC 1430657 (5a) contains the supplementary crystallographic data for this paper. This data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam. ac.uk/data request/cif. See also the Supporting Information.